Podcasts about chief scientific advisor

Ever wondered about the intersection of policy and science? Tune in as Markella chats with Professor Andrew Millar about his career and work as the Chief Scientific Advisor on the environment, natural resources, and agriculture for the Scottish Government. Interview and editing by Markella, art by Keiran, and production by Manushri. 

Welcome back to the Flex Diet Podcast! I'm Dr. Mike T. Nelson, and in this episode, I sit down with Dr. Hamal Patel, Chief Scientific Advisor to Discovery and the brilliant mind behind the ME screen blood test for mitochondrial function.We dive into Dr. Patel's fascinating journey into the world of mitochondrial research, how mitochondria impact everything from metabolism to resilience, and why he developed a personalized blood test to better understand mitochondrial health. We also get into some really cool topics like how heat and cold exposure affect your mitochondria, the intersection of meditation and cellular health, and even the emerging role psychedelics might play in this space.Dr. Patel also shares his top tips for optimizing mitochondrial function and explains the science behind this cutting-edge testing method. If you're curious about performance, longevity, or just want to geek out on mitochondria with two scientists, this episode is for you. Let's dig in.Sponsors:Tecton Life Ketone drink! https://tectonlife.com/ DRMIKE to save 20%LMNT electrolyte drink mix: miketnelsonlmnt.comDaily Fitness Insider Newsletter: https://flex-diet.kit.com/bfa1510fa8Flex 4: Dr. Patel's top 4 recommendations to improve mitochondriaTriphasic 2 book now available!Go to https://triphasic2.com/Episode Chapters:05:51 Dr. Patel's Journey into Mitochondrial Research08:34 Heat and Cold Stress in Mitochondrial Function12:18 Mitochondrial Function and Health19:50 Innovative Mitochondrial Testing31:05 Understanding Mitochondrial Respiration31:20 Testing Mitochondrial Efficiency31:51 Energy Production Pathways32:24 Free Radical Generation and Stress Testing32:58 Exercise Physiology and Mitochondria33:50 Personalized Mitochondrial Health Recommendations33:59 The Complexity of Mitochondrial Adaptation37:28 The Role of Membranes in Mitochondrial Health38:49 Oxygen's Dual Role in Life and Aging41:05 Preconditioning and Cardiovascular Health43:07 Hypoxic Training and Breath Work43:50 Meditation and Mitochondrial Function48:03 Psychedelics and Mitochondrial Changes54:33 Practical Tips for Mitochondrial Health56:12 Conclusion and Final ThoughtsFlex Diet Podcast Episodes You May Enjoy: Episode 164: How to use diagnostic testing to improve your metabolic health: An Interview with Sam MillerEpisode 190: Let's Get Woo Woo – From Physics To Scientific Testing To Exercise Performance with Ian Mitchell of Wizard SciencesConnect with Dr. Patel: Instagram: https://www.instagram.com/hemalpatelphd/Website: https://mescreen.com/Enter code DRMIKE to save $100 - I don't make a dime off it. I would love to hear what you find, so hit me up if you try it!Get In Touch with Dr Mike:Instagram: https://www.instagram.com/drmiketnelson/YouTube: https://www.youtube.com/channel/UCn1aTbQqHglfNrENPm0GTpgEmail: https://miketnelson.com/contact-us/

Dr. Eric Kmiec is Director of the Gene Editing Institute of the Helen F. Graham Cancer and Research Institute at Christiana Care Health System. He also holds faculty appointments at the University of Delaware and the Wistar Institute. Eric and his colleagues are working to develop new ways to treat cancer by destroying the genes that cause cancer cells to be resistant to typical therapies like chemotherapy, radiation, or immunotherapy. Throughout his life, Eric has enjoyed sports. He particularly likes playing baseball and hockey, and he still plays baseball competitively in a league in Philadelphia. Eric also spends much of his time doing landscaping and yard work. He Received his B.A. in Microbiology from Rutgers University, his M.S. in Cell Biology and Biochemistry from Southern Illinois University, and his Ph.D. in Molecular Biology and Biochemistry from the University of Florida School of Medicine. He conducted postdoctoral research at the University of Rochester before joining the faculty at the University of California, Davis in 1987. Since then, he has served on the faculty of Thomas Jefferson University, the University of Delaware, and Delaware State University. In addition, Eric founded, consulted for, and served as Vice President of Kimeragen, Inc., he was Chief Scientific Advisor for the Genomics Division of Tapestry Pharmaceuticals, was an Eminent Scholar and Director of the Marshall University Institute for Interdisciplinary Research, and also served as Co-Founder, Chief Scientific Officer, and a Board Member of OrphageniX. Eric has received numerous awards and honors over the course of his career, including receipt of the 2012 Proudford Foundation Unsung Hero Award in Sickle Cell Disease, designation as an Honorary Commander of the 436th Air Wing at Dover Air Force Base in 2013 and 2014, and also induction into the Southern Illinois University, Edwardsville Alumni Hall of Fame in 2012. Further, Eric and the team at the Gene Editing Institute were recently awarded the inaugural Life Sciences and Bio Innovation Award from the Philadelphia-Israeli Chamber of Commerce. In our interview, Eric shared his experiences in life and science.

In the latest episode of Approximately Correct, we're taking the time to celebrate with Amii Fellow, Chief Scientific Advisor, and Canada CIFAR AI Chair Rich Sutton, newly-minted winner of the A.M. Turing Award, a prize that is often referred to as  the “Nobel Prize of Computer Science.”

The Smart 7 is an award winning daily podcast that gives you everything you need to know in 7 minutes, at 7am, 7 days a week...With over 17 million downloads and consistently charting, including as No. 1 News Podcast on Spotify, we're a trusted source for people every day and the Sunday 7 won a Gold Award as “Best Conversation Starter” in the International Signal Podcast Awards If you're enjoying it, please follow, share, or even post a review, it all helps...Today's episode includes the following guests:GuestsSir Keir Starmer MP - Prime Minister of the UKPeter Kyle MP - The Secretary of State for Science, Innovation and TechnologyIvana Bartoletti - Global Chief Privacy Officer at WiproDr Maxine Mackintosh - AI & Health Expert at The Alan Turing InstituteAlex Stephany - Entrepreneur & CEO of BEAMWill Guyatt - The Smart 7's Tech GuruMohammed Akbar Hussain - Consultant Neurosurgeon at Royal Victoria Infirmary NewcastleTim Cook - CEO of AppleProfessor Lotte Knudsen - Researcher & Chief Scientific Advisor at Novo NordiskProfessor Francesco Rubino - Chair of Metabolic and Bariatric Surgery at King's College LondonDerrick Pitts - Chief Astronomer at The Franklin InstituteKane Christensen - Spider Expert at the Australian Reptile Park​​Professor Kris Helgen - Director of the Australian MuseumContact us over at X or visit www.thesmart7.comPresented by Ciara Revins, written by Meg Turner and Liam Thompson and produced by Daft Doris. Hosted on Acast. See acast.com/privacy for more information.

Series Five This episode of The New Abnormal podcast features Epaminondas Christophilopoulos, who is a Foresight, Strategy, Innovation and long-term planning advisor to government, private corporations and NGOs. A highly experienced foresight researcher with an extensive track-record on international projects and sound academic credentials, he's an expert on internationalization and research commercialization, and has managed projects in Asia, Latin America, and Africa. With a track record on several boards and expert advisory role in public policy institutions in Innovation, Culture, Agrofood, Environment, Security; Epaminondas is a UNESCO Chair on Futures Research, the President of MOMus, and is the ex-Chief Scientific Advisor for Foresight to the Greek Prime Minister.In this episode we cover all of the above, along with his views on a range of catalytic issues being discussed in futurist-circles in 2025. And, as a bonus, he also discusses 'Russian Cosmism' a radical biopolitical utopian perspective espoused by the philosopher Nikolai Fedorov in the late 19th C, in which he 'rejected the contemplative for the transformative, aiming to create not merely new art or philosophy but a new world'. So...enjoy!

Skip the Queue is brought to you by Rubber Cheese, a digital agency that builds remarkable systems and websites for attractions that helps them increase their visitor numbers. Your host is Paul Marden.If you like what you hear, you can subscribe on iTunes, Spotify, and all the usual channels by searching Skip the Queue or visit our website SkiptheQueue.fm.If you've enjoyed this podcast, please leave us a five star review, it really helps others find us. And remember to follow us on Twitter  or Bluesky for your chance to win the books that have been mentioned in this podcast.Competition ends on 22nd January 2025. The winner will be contacted via Twitter or Bluesky.  Show references:https://litlablondon.wixsite.com/lit-laboratoryhttps://www.instagram.com/litlablondon/https://www.threads.net/@litlablondonhttps://www.linkedin.com/company/litlablondon/https://www.facebook.com/people/The-Lit-Lab/100090991921959/ Abi Fafolu has a Master's degree in Bioengineering from Imperial College, and over 7 years' experience in public engagement with science. She spent her early career in science engagement, including on the Science Desk of The Guardian Observer and promoting open-access publishing at the European Medical Journal and Springer Nature.Since joining the UK government in 2015, she's worked in strategy, policy and programmes across four government departments including the Office of the Government's Chief Scientific Advisor, Lord Patrick Valance, upholding the role of science and evidence in decision making, and promoting developments in science as a Press Officer to the UK Science Minister. Abi is currently a government policy and strategy maker, and runs the Lit Laboratory (Lab), a "Science and Sip” experience reconnecting underrepresented audiences aged 21 to 40 with science. Transcription:  Paul Marden:  Welcome to Skip the Queue. A podcast for people working in and working with visitor attractions. I'm your host, Paul Marden. Paul Marden:  In today's episode I'm joined by Abi Fafolu, Founder of The Lit Lab. Abi has a Master's degree in Bioengineering from Imperial College, and over 7 years' experience in public engagement with science.Since joining the UK government in 2015, she's worked in strategy, policy and programmes across four government departments. She currently a government policy and strategy maker, and runs the Lit Laboratory, a "Science and Sip” experience reconnecting underrepresented audiences aged 21 to 40 with science.Unfortunately the internet wasn't kind to us when we recorded this conversation, and so the audio quality isn't great, but the conversation definitely was.Paul Marden:Welcome, Abi. Welcome to Skip the Queue.Abi Fafolu: Thanks, Paul. Thanks for having me. Paul Marden: Lovely to have you. Today's a little bit weird because we're recording this just before Christmas, but it's not actually going to go out until the new year. So what I'm going to say is happy New Year to you. I hope you've had a lovely Christmas, but the reality is we haven't had it yet. So strange. Abi Fafolu: Thank you and likewise. Paul Marden:So we always start our interviews with some icebreaker questions which you're never prepared for. So here goes nothing. I've got a couple for you. I think they're quite nice ones actually. What's your go to coffee order when you go to a coffee shop of your choice? Abi Fafolu: Embarrassingly, I saw a skit about this recently where I thought that I had a unique choice, but clearly I've been very moth by the Internet. It is a skinny flat white and the skit that I saw actually was people ordering hot chocolate, which has gone extinct in coffee shops. I think there were a few people doing kind of hot chocolate watching. They were seeing where the people would order hot chocolates and have the binoculars out to watch those people as they made that rare order in the shop. But no, mine is very common. It's a skinny flat white. Paul Marden: Yeah. So mine is just a normal straight up flat white. No nonsense, no fuss, just give me coffee. I just want a nice coffee. My daughter, her order, she's only 11, but she's taken to iced hot chocolate. But what do you call it? Is it iced chocolate like an iced coffee or is it iced hot chocolate? I always stumble over the order and it's never up on the menu. So I always feel a bit awkward asking for whatever it is that she wants. Abi Fafolu: I like that. Paul Marden: Yeah. Okay, next one. What animal do you think best represents your personality? Abi Fafolu: Oh, gosh, I'm probably like a reliable owl or something like that. Yeah. Kind of cosy in my tree when I feel like it, being a bit nosy and flying out to have a look at what's going on. Paul Marden: And every now and again savage on little animals. Abi Fafolu: Oh. I mean, maybe a bit of that, probably. But yeah, I think something like that. Paul Marden: Okay. I think mine would have to be one of those, one of those dogs that is really annoying and full of energy because I'm just, I'm always at like full power. I'm one of two extremes. I'm going full at it. Yeah, I'm just zonked out, shattered at the end. Yeah. Abi Fafolu: Okay. Paul Marden: So I'd probably be like a springer spaniel where loads of walking is necessary to get rid of all the energy. Otherwise I'll be really annoyed.Abi Fafolu: Got you. A little dog who doesn't know that they're little and springs out into the world. Paul Marden:I'm sure there's something Freudian about that. I'm not sure. So we are talking a little bit about your project called the Lit Lab today which as listeners will know I always have a little chat with people before we do the interview and you know, I'm really interested in this concept, the tagline that you talked about which was the idea of getting adults to drink in a Science lab. We first met at the Association of Science and Discovery Centres and you know, we had a lovely conversation whilst were at the ASDC conference and I found out a little bit more about Lit Lab. But I think before we get to that point let's just talk a little bit about you and your background. So tell us about you. Tell us about your background and maybe a little bit about day job. Abi Fafolu: Yes, of course. So I am a Scientist by training. I have a Master's degree in Bioengineering from Imperial College and about 7 years experience in public engagement with Science. So that has looked like working on the Science desk of the observer newspaper, publishing medical research at Spring and Nature, working with the Chief Scientific Advisor and in government and with the Science Minister as well doing kind of comms and press releases. At the moment I work in strategies by working thinking about where my organisation wants to get to and how we do that. And for me I think it probably brings together a lot of the skills and interests I have. Abi Fafolu: It's really about kind of seeing that bigger picture and wondering how things come together and wondering what things will be different and kind of looking at the evidence and friends and things that are going on that help to paint a picture actually of kind of what the options are and gives you a sense of what's possible. So I think there's a thread really through my kind of career history which is a lot about being nosy and having that kind of owl sand view of the world. And yeah, I think my kind of interest and passion in and Science has also kind of given me a lot as well in the subject and things that have piqued my interest. Paul Marden: I think it's such an interesting opportunity for you to being in public policy and Science within government over the last few years. It's a really interesting perspective and it's the kind of career that no kid at school would ever dream is a career. Yeah. You know, kids at school can imagine being a chemist or a biologist, they can relate to that. But the idea that Science exists at the heart of government and influences everything the government does is not something that your average kid would think about doing. So how do you end up falling into a role like that? Abi Fafolu: Yeah, well, I mean, I suppose my reflection on what you've just said is sort of. So I think for me, you know, I'm currently the only person in my network who has a background in Science, so I didn't really have a clear picture of what it would look like to be a Lab Scientist. You know, you do those practicals at school, you meet teachers and, you know, lab assistants who are, you know, models of that for you. But I didn't know anyone that did that sort of work and I wasn't sure if I was good at it. I just knew that I enjoyed it. Abi Fafolu: And I think when I stumbled across the idea that actually there's a whole strand of Science that's about communicating with people, what's going on, about bridging that gap, really, between the doing and the using of Science, that, for me, opened up a whole new world. And a lot of the kind of journey I suppose I've been on in my career is thinking about how to really help people see the impact of the Science in their everyday life. So I think, you know, in publishing, you're at the forefront of all the developments, you see everything that's going on and it's really interesting. But the average person on the street, you know, has no idea how to apply bioengineering techniques that are, you know, novel and coming out of the lab for their everyday life. Abi Fafolu: But then when we have a situation like Covid, where we're starting to look for novel ways to make vaccines, you know, that's the sort of application, I suppose, of the work that people are doing and the interest that drives them. So for me, I think following that curiosity into this kind of world of Science engagement has been a bit of a journey. Paul Marden: So that leads nicely to the association of Science and Discovery Centres, how we met at their conference. There was a lot of talk at the conference, wasn't there, about public engagement? How do we enrich people's lives with Science and help people to feel that Science is part of their them and that they can influence the Science decision making and the direction that Science takes over the next decades. You're a trustee of ASDC, so what does that involve? Abi Fafolu: Yeah, you've said it really. But ASDC's mission is absolutely that, to make Science accessible and inclusive for more people and to be seen as a valuable part of everyday life. So their role broadly is to kind of bring together and support Science engagement centres, discovery centres and other spaces like that together. And I know you've had probably doing a wonderful job of explaining what ASDC does and the value it brings. I won't go too much into that, but as a trustee, I suppose the core of that role is to give support and challenge to the CEO. I suppose you think of it as, you know, a CEO doesn't really have colleagues or peers and so, you know, we're head trusted advisors in her, in this case. Shaaron ASDC. Abi Fafolu: We are the people that help the sense tech decisions and make sure the organisation is living up to its purpose. Paul Marden: Absolutely. So that's a little bit of background. Let's talk about the Lit Lab. Explain to our listeners who know nothing about the Lit Lab. What is it? Let's start with the broad picture of what it does. Abi Fafolu: Yeah, yeah, sure. So the Lit Lab is the UK's first Science and bit. It is a laboratory or Science themed social event where people do fun homestyle Science experiments, make drinks and take part in kind of friendly challenges. It's a social event that is something I do alongside my day job, as I mentioned. And so it runs quarterly at the moment. But essentially people arrive or kind of pop up Science lab, usually in the basement of a bar or a pub. We've done bigger venues like box parking spaces like that as well. But when they arrive they will find kind of their own lab coat and goggles waiting for them. They might get a drink at the bar while they settle in and then we have a host and lab assistant who will walk them through three experiments and two games. Abi Fafolu: So we always start with a drink, we make a drink. We call that our kind of molecular mythology series. So anything from kind of dry ice cocktails, cool kind of layered drinks and then we end with an explosion. So yeah, some of our more popular ones tend to be ones that involve a bit of cleanup at the end. So that's kind of the model for the event and it's really about helping adults to reconnect with Science and have a good time doing it. Paul Marden: Excellent. So you're taking this out into pubs and bars. It sounds like a Science centre in the back of a van or something. So what sort of kit are you taking with you into the event spaces? Abi Fafolu: Yeah, I mean you're not far off with the kind of back of a van analogy. I have a garage full of labware.  But my neighbours always look at me a bit suspiciously when I start to pile up my pipettes and bits of lab coats and that sort of thing. Paul Marden: Awkward conversations with the neighbours as they're watching what you're taking out the garage. Abi Fafolu: I mean, if I suddenly see flashing lights at my door, I'll probably have a sense and someone's got the wrong end of the stick. But no, we, as I said, you know, kind of a small pop up and so really it's a startup and it's got all of the kind of all that comes with that. So, you know, storing lots of kit in my garage means that the event is intimate because there's only so much, you know, test tubes and beepers and chronicle class I can fit in one space. And then we're on the day, kind of a group of lab assistants and me who will set up the stations for guests. So, you know, for different experiments where we're really trying to replicate, you know, the type of materials and tools that you would use to explore the same sort of things. Abi Fafolu: So one of the things that we do in the lab is DNA extraction with home style ingredients, things that you can find in your skin do with skids. But we're using, you know, conical glass and pipettes and syringes so that we're really being accurate with our measurements and people have that chance to get stuck in. Abi Fafolu: But we don't do any tutorials. It's not, it's not a lesson. It's really for people to get hands on and try things out for themselves. So we give them a QR code that they scan for instructions and it will tell them kind of what the stats are. But you can take that all either, you know, you've got all this in front of you and if you want to mix some things together and see how it goes, then that's the, you know, that's the spirit of Science. They're more than happy for people to do that too. Paul Marden: Excellent. So where did the idea come from? How did, how did you come up with the idea for the lit lab? Abi Fafolu: So it's like a lot of people thinking about kind of, you know, what they want to do with themselves and kind of what skills they have and things they're passionate about. Particularly kind of post lockdown where, you know, you had a lot of time to reflect and think about whether you were making the most of, you know, your skills and abilities. I was seeing a lot of kind of social events come out that were particularly focused around sort of activities. People, I think, wanting a bit more purpose as well when they do leave the house, because that was a luxury. We didn't take for granted that when we step out, we're spending time and that means so much. So a lot of activities that people were doing were things like pains and sips. Abi Fafolu: So this is the model, really, that I've reprised, where people buy tickets to an event and they create art and have drinks and really, it's a model that's really growing globally. So I think that the market in America is in the millions, if not billions, as a kind of global event concept, and definitely picking up here as well, but you see it kind of taking off in different formats. So there are pottery and sips and D Day and sips and all sorts of things like this. And so for me, I kind of. I looked at that and I thought, I think I should do something like this, too. And so I spoke to kind of friends and family and I said, I kind of wanted to try out this thing. I think I could make something similar here. Abi Fafolu: And so I got together a group of friends at my mum's church hall, bought some lab coats from Amazon and spent absolutely ages writing loads of Excel sheets about the experiments that we could do and what I need to buy to kind of get that together, and had them for far too long for an evening after work, doing all sorts of great experiments. And they loved it. Abi Fafolu: They thought it was. It was great and really fun. And so, yeah, it kind of took off from there. I thought, you know, this maybe might be something that we can bring to more people. And so since then, with, I think, about 300 guests, we've got, I think, sort of a thousand or so followers on social media. We've been in timeout London and Secret London magazines and that sort of thing. So, yeah, I think it's reaching some of the right people, but I think you could do more. Paul Marden: So for me, I think there's something about it that really attracts me. I'm an extroverted introvert, so I like to be around other people, but it can be challenging going into a new social situation. For me, I might not feel comfortable. What makes me feel comfortable is being in the context of having a shared mission with people. Paul Marden: So the idea of, you know, having these experiments to conduct with people, there's something to focus on rather than just the people that are around you. And you know, I need to speak to everybody. I need to be the life and soul of the party. No, no, I'm focusing on this thing. And the social element of just being with other people happens around you when it's done at its best because it's not taking all your conscious effort. Your conscious effort is focused on this thing that's in front of you. You and the rest of it is just blossoming around you. Abi Fafolu: So yeah, no, absolutely. I think the other part of that is that you're in a room with people with similar interests. Right. You're creating community. There are people there that are really excited and curious about kind of rekindling that passion that they had for Science or that interest that they had. And so there's a real energy of people kind of wanting to get stuck in and being excited kind of for every thing that we bring out. And yeah, it absolutely is, you know, part of my plan for it to be able to build a bigger community around it. And we have some of that online. Abi Fafolu: So there's a lab Patreon site where we share Science news, blogs about kind of running a pop up Science lab, you know, behind the scenes and really helping people to reconnect with Science, even if they're not in that space with people, but also just to find that community with that said interest. Paul Marden: So you come up with these spreadsheets at the beginning. You tracked all your mates in a church hall for the first evening. Was there a lot of experimentation involved in. I'm a meta level here. Yeah, experimentation around the experiments that you want to run. Were there some that you did that just weren't successful? Abi Fafolu: Oh yeah, absolutely. Yeah. So I do have a mega spreadsheet of kind of experiments like I could do a lot of the ones with fior. I've had to rule out the various disappointingly. But we'll see how we can get around that in future. But no, absolutely, there's the constraints of, you know, the idea of this is that a lot of the Science is home style and you could absolutely kind of go home and replicate that. One of the things that we do online is created tutorial videos used to try some of the experiments from the lab. And so what I don't want is to have to find kind of lab grade chemicals because that's not homestyle Science. Paul Marden: No. Abi Fafolu: And so I really want it to be accessible in the truest sense. And so that's a, you know, a philtre for me when it comes to thinking about what sorts of things we could do as much as possible as well. You know, having experiments that have real world kind of application or implication. I talked about the kind of DNA one, you know, the method that we use for that at home is really similar to what we do in the lab. It just has, you know, different types of reagents, you know, more specialised or more tailored to doing that. But yeah, I think being able to really kind of illustrate kind of core concepts in Science as well as do them with materials and things like that are accessible is a strong philtre for me. Abi Fafolu: But thinking about some of the ones, I suppose that haven't made the cut. And as I say that actually I should say that we do have a kind of core set of experiments as well as seasonal ones. So the most recent event was Halloween and we started by making blood transfusion cocktails. So we had blood bags with grenadine in them. We did a kind of gruesome DNA extraction with picking livers, we made potions that are wrapped to finish off the session, that sort of thing. But yeah, a lot of the ones that are kind of more temperamental, I guess, and not so resilient for people who are not going to read the instructions are the types that don't quite make it in. And they can be things like, you know, dry ice doesn't last forever, it eliminates, it evaporates quite quickly. Abi Fafolu: And so there are things like that where, you know, over the course of the kind of two hour event maybe is not the best type of experiment to try and do because by the end of it some people will still have dry ice and some people won't. And I'm not, you know, I'm not in a degree where I can, you know, just turn the corner and get some more. So yeah, some of them are just kind of practical, why they don't quite make the part. But yeah, definitely a longer list of things I try with more opportunities to do. Paul Marden: I talked a little bit about why it piques my interest. But who is the audience that you're seeing coming along to events? Abi Fafolu: Yeah, so I think both from kind of attendance at events and you know, the feedback that we get and the kind of data from that, but also our insights from social media and things like that. We can see that the audience is largely women. So about 70% women age between 21, maybe 45. Interest really in Science culture, trying new things, meeting new people. And I'm especially interested actually as well in targeting minority audiences. So the women, but also black and ethnic minority people who are underrepresented in Science, who maybe, you know, don't have access to Science and that sort of discourse and really just to change perceptions about who Science is for. So I think the idea that you can do Science outside of a classic setting, outside of a lab, outside of research, outside of academia is really important to me. Abi Fafolu: So, yeah, I think it's a broad audience and I think Science is absolutely for everyone. But part of my mission is also to make sure we're reaching some audiences who aren't really. Paul Marden: That's the audience. Are you doing, is this a solo effort for you or have you got teams of lab rats that come along and help you? Abi Fafolu: And so I'm a solo entrepreneur, I am the founder, one of those hats. But on the day of the event I do have a team, we call them lab assistants rather than lab rats. But I do have a team of people who are amazing at preparing the experiments. People so they can get stuck right in troubleshooting any kind of niggling issues, you know, with the experiments on the day and making sure that people kind of know what they're doing. And for me, actually it's been really important to open those opportunities up to up and coming Science communicators. So, you know, people who want that experience really in practising and engaging the public directly with Science. Abi Fafolu: And again, you know, there's nothing quite like this at the moment, so I'm hoping, you know, that's a good opportunity for them as well to kind of pick off those sorts of careers. Paul Marden: Yeah, it's quite nerve wracking, isn't it, doing what you're doing, stepping into a sector where. Or creating your own segment. Yes, you're taking inspiration from things that already exist, but nobody else is doing this. And you've got. It's at the core of being entrepreneurial, isn't it? You've got to test the market and experiment to see where it goes. But that can be quite nerve wracking. So having that team of lab assistants, those people that are helping you on the day, you know, it's invaluable because you can't have eyes in the back of your head when you're at the event, it's really, you know, it's really hard, I guess, to be able to run one of these events, keep it all flowing, solve the problems and be a gracious host at the same time. Abi Fafolu: Yeah, absolutely. And I should say, actually I'm not the host, so I am very much kind of in the background for the events themselves, they are hosted by. I have a few different people that kind of tap into this role, but essentially they're presenters and people whose job it is that have that sort of MC role to keep the crowd engaged and enthused. And again, like I said, they don't teach, they don't set out. Kind of made the story of what we're going to do, but they encourage and, you know, prod and make jokes with the group and that sort of thing. One of the elements of it that I think works well as well is that we try to introduce kind of competition. Abi Fafolu: So if we have, you know, two or three tables, depending where we're doing it, you know, each table is a group that competes and they choose a table name which is made up of a range of things that might be for that month, elements in the periodic table, their favourite horror movie and their favourite brand of alcohol. So they get kind of wacky table names and earn points as they go along. And we actually, for most events, compete for spots or fleets. So if you're a winning table, you'll find a rap of spots coming your way. So, yeah, it's definitely a social event I think we major on as well as Science in our event. Paul Marden: Of course, it does sound a little bit like a kind of classic Science communicator role at the Science Centre, doesn't it? You know, that job to engage people in Science. But you're hiding. You're hiding the vegetables, aren't you? They're learning a little bit about Science, but at the same time they're enjoying themselves and you've got to major on the enjoyment and engagement, otherwise they're never going to learn something. Abi Fafolu: Yeah, no, I absolutely agree with that. And we provide some of that background to people that want it. So, you know, in the same way that you can scan the QR and find out what the instructions are, you can also scan and find out kind of what the Science is behind what you're doing. Because I think, you know, if people are particularly curious, you want to make sure that they have the opportunity to follow up. Paul Marden: Yeah. So you're taking this out to pubs and bars. Have you got future plans to try other types of spaces or to take this to other places? Abi Fafolu: Yeah, so I know that you we're alluding to as well, the kind of theme of this. So, you know, absolutely, we're doing Science, but this is. This is culture, this is creativity, this is all of the things that, you know, make Science real and enjoyable for people as well. So Absolutely. I see it as a kind of creative cultural endeavour. I've done a few events in sort of different contexts. I, for example, was just running a winter fair event called University of East London. And that, I think, gives us the opportunity to have people kind of zip in and out from what we're doing and see it in the context of other things as well. And I think this brings to the forefront even more that, you know, this is something that's for entertainment. Abi Fafolu: You know, like, there's education here, that this is an entertainment concept. So, yeah, I think it really has a place in lots of different spaces and I think there's lots of opportunity, really, to see where it can go. Yeah, absolutely. Would love to work with different types of venues, so universities. But also there are these other cultural institutes, talking museums and places like that, where I think there could be a really nice partnership opportunities there. Paul Marden: Yeah, absolutely. There's an element of. And it was something that somebody said at the ASDC conference. It was one of the questions that got asked at the Skip the Queue episode was all about getting the A into STEAM. So getting. Getting the Art into STEAM. Subjects. There's an element of if you could take this into a bar and a pub, you can take this into art institutions, to galleries, to museums, other cultural institutions. All these sorts of institutions are looking for ways in which they can extend their reach, that they can. Can serve different audiences, generate revenue for themselves at times when the institution is quiet. And this is just a lovely concept to be able to pop the things in the back of the van and take it to institutions and help them to do those things. Abi Fafolu: Yeah, thank you. And I think, just to add to that, I think we're definitely seeing a rise of that with the kind of museum lakes. It's a theme across lots of different venues completely. And. And it's absolutely that. It's about the kind of adult market and recognising, I think that, you know, just because you're an adult doesn't mean that you can't still have fun with the things that you were interested in as a younger person or, you know, hobbies that you don't have the opportunity to do. So, yeah, Science is a hobby, definitely something I'm all the way behind. And I think the kind of adult space is a really good opportunity for that. Yeah. Paul Marden: Oh, completely. I get to masquerade behind my daughter. I'm taking her to Science centres for her benefit. But the reality is I have a whale of a time and I love going to the Science central, Science museum And I'd feel a bit odd going as a single bloke wandering around some of these institutions on your own during the daytime. It might not feel quite right. But a Science late event, I could totally, you know, I've done enough ASDC events at Science centres where we've had the evening meal in a Science centre in the evening and it's been delightful to wander around these places in the evenings. There's a huge amount of opportunity at your local Science centre to find things that engage adults as well as kids. Abi Fafolu: Yeah, absolutely. Paul Marden: What are your goals? Where do you want to take the Lit Lab for the future? Abi Fafolu: Yeah. So, I mean, again, this concept of kind of popping things in the van and kind of rocking up wherever is definitely a perk of the current model, but it still sort of means that at the moment, you know, the little ad is in London big as I am, you know, I don't want that to be a kind of barrier for it and I definitely don't want it to stop the right people from reaching it. So for me it would absolutely be that to be able to reach more parts of the country and particularly, you know, like the cities of culture. I'm thinking that, you know, the Bristols and the Manchesters and the Bradfords next year as the 2025 or this year. Paul Marden: That was slickly done. Well done. Abi Fafolu: Yeah, I think, you know, being able to meet people where they're already exploring these interests and then hopefully see that Philtre out as well would be wonderful. Paul Marden: Okay, so is that partnership model or is that a kind of a franchise model or are you open to conversations with people about how you could deliver this? Abi Fafolu: Yeah, no, absolutely open. I think that's, you know, a perk of being. Being the first, isn't it? But, yeah, all things are on the table and I think that's a wonderful thing. You know, I'm probably still in the. It's my baby face. I can imagine. I can imagine that there's probably a bit of hand holding that would. Would come before any. But yes, I think absolutely open. Paul Marden: Yeah, that's interesting. Well, look, it's been lovely talking to you, finding out a little bit more about you and finding out more about The Lit Lab. I think it's such a wonderful concept. I feel a team rubber cheese evening event coming along soon where I think we bring the team and we do a little bit of Science together. I think that might be a nice idea. Abi Fafolu: Idea more than welcome. I'd love that. Paul Marden: So we always ask our guests to give us a book recommendation. So Abi, what's your recommendation for the listeners today? Abi Fafolu: Yeah, I had a good think about this and you know, in all that I've talked about, I think there's probably also something about reclaiming this kind of nerd label. I think my recommendation is probably going to fall in that space, but I'm happy with that and I own it. But mine is in the genre of sort of mythology, magical realism, fantasy, and I really love Greek mythology. But I'm actually also getting into African mythology, of which there are loads of kind of classic but also kind of up and coming writers. And one that I'm really enjoying now is called She Would Be King by Wayétu Moore. And it's a story of basically the kind of creation of a new space in Liberia during the kind of transatlantic slave trade. Abi Fafolu: And it basically imagines the stories of the three different people in a sort of anthology way, who get powers as they go through the real horrible and inhumane kind of trials of, you know, being part of that. So from America to Jamaica to West Africa, you know, these three people go through different experiences of that and they all get powers that help them to cope with that. And it draws on the types of powers that you might see in African mythology. So it's a really beautiful book and a really inspiring and kind of educational one too. I think there's a lot of, you know, factor accuracy in terms of, you know, what happened and the types of experiences that people accounted. Yeah, that's one of my definite recommendations and I'm actually rereading it at the moment. Paul Marden: Wowzers, listeners. So if you'd like a copy of the book that Abi recommends, normally I'd say get over to X and repost the show announcement on X, but you can do that on bluesky now. So go find us. We are @skipthequeue.fm on Bluesky and do whatever you do to repost a notice on bluesky and say I want Abby's book. And the first person that does that will get a copy of Abi's book sent to them as a gift from us. And I'll be very excited because we'll have more followers on Bluesky. X is a bit of a dumpster fire now, so we are moving rapidly to Bluesky. Abi, it has been delightful to meet you. Paul Marden: If listeners would like to find out more about the Lit Lab, all of your links and your socials and the website will all be posted in the show notes. So listeners, you'll be able to go and find out about where the next Lit Lab events are all on Abi's website. It's been lovely to meet you. Thank you ever so much for coming on the podcast. Happy New Year. Abi Fafolu: Thank you so much. Paul. Thanks so much for having me. And Happy New Year to you too. Paul Marden: Thanks for listening to Skip the Queue. If you've enjoyed this podcast, please leave us a five star review. It really helps others find us. And remember to follow us on Twitter for your chance to win the books that have been mentioned. Skip The Queue is brought to you by Rubber Cheese, a digital agency that builds remarkable systems and websites for attractions that helps them increase their visitor numbers. You can find show notes and transcriptions from this episode and more over on our website, SkiptheQueue.fm. The 2024 Visitor Attraction Website Survey is now LIVE! Dive into groundbreaking benchmarks for the industryGain a better understanding of how to achieve the highest conversion ratesExplore the "why" behind visitor attraction site performanceLearn the impact of website optimisation and visitor engagement on conversion ratesUncover key steps to enhance user experience for greater conversionsDownload the 2024 Rubber Cheese Visitor Attraction Website Survey Report

The Chief Scientific Advisor at Novo Nordisk, Lotte Bjerre Knudsen, was the key force who pushed hard to develop GLP-1 drugs for treating obesity and subsequently for Alzheimer's. She was recently recognized by the 2024 Lasker Medical Research Award, and the 2024 AAAS Bhaumik Breakthrough of the Year Award. That recognition is richly deserved, since it is unclear if the GLP-1 drug path to obesity treatment, and all of the associated benefits, would have been seen at this time without her influence. That's especially true given the mystery for why people with Type 2 diabetes (for which these drugs were used for many years) did not exhibit much in the way of weight loss. We discussed that and the future of these drugs, including their potential to prevent neurodegenerative diseases. And about dressing up in pink!The Ground Truths podcasts are also available on Apple and Spotify.Our entire conversation can also be seen by video at YouTube along with all of the Ground Truths podcasts. If you like the video format, please subscribe to this channel. Even if you prefer video, please take a look at the transcript with graphics and useful links to citations.A Video Clip below on the barriers of a woman scientist to push Novo Nordisk to develop GLP-1 for obesity. “I was always just been a nerdy little scientist who kind of found home here in this company for 35 years.”—Lotte Bjerre Knudsen, 60 MinutesTranscript with Links to audio and external referencesEric Topol (00:06):Well, hello, it's Eric Topol with Ground Truths, and I have with me a special guest. She's the Chief Science Officer of Novo Nordisk and it's Lotte Bjerre Knudsen, and we're delighted to have her. She's a recent recipient of the Lasker Award, which I think is considered like the pre-Nobel Award here in the United States. And I was involved with her in terms of researching who was the principal person who brought the GLP-1 drugs to the forefront for obesity, and it turned out to be Lotte. So welcome, Lotte.Lotte Bjerre Knudsen (00:48):Thank you very much. And also very, very happy to be here. I'm not the Chief Science Officer for Novo Nordisk, I'm the Chief Scientific Advisor of working for the Chief Science Officer of Novo Nordisk, but maybe too many people, not so different, right?From Laundry Detergents to GLP-1 DrugsEric Topol (01:06):Yes. Thank you, I actually meant to say advisor, but yes, I'm glad you cleared that up. I know from speaking to some of your colleagues, I actually spoke to Robin yesterday that you are looked to very highly, the most highly regarded person in science there, so not surprisingly. What I want to do is first talk about the glucagon-like peptide-1 (GLP-1) that got its legs back in, I guess 1984. So we're going way back. And what's also interesting is that you go way back at Novo Nordisk to 35 years in 1989. And so, there had been this work with this extraordinary hormone and neurotransmitter with a very short half-life that you knew about. But when you first started in Novo Nordisk, you weren't working on this. As I understand it, you're working on laundry detergent enzymes. How did you make this pivot from the laundry enzymes to getting into the GLP-1 world?Lotte Bjerre Knudsen (02:16):Yeah, thank you for that question. I'm from the technical University of Denmark, so I'm trained in biotechnology, and we're a small country, so not that many companies to work for. And I always had my mind set on, I wanted to work for Novo as it was called back then, and it just happened to be in the industrial enzyme part that I got my foot in first. And then I had a very interesting boss at the time. Unfortunately, he's not alive anymore, but he was both a medical doctor as well as a chemist. So he was actually put in charge of actually, let's see if we can do something new in diabetes. And then since he hired me and I had not been there that long, I simply tagged along as the youngest scientist on the team, and then suddenly I became a diabetes researcher. Around the same time, I think you remember that all of pharma was interested in obesity in the early 90s, everyone wanted to do diabetes as well as obesity, but they were separate teams and they all wanted to do small molecules, but it just happens to be so that the best idea we could find at that time was actually GLP-1, because we actually had clinical data relatively early that GLP-1 was a really good candidate as a treatment for diabetes because of the glucose sensitivity of the actions.(03:43):So you'd have efficient lowering of glucose through a dual mechanism with increasing insulin, lowering glucagon, and then it was safe because there wasn't this hypoglycemia you get from insulin. But then I had other colleagues who were working on obesity, and I was just kind of listening, right, what's going on there? And then also a colleague that I had, we had, I don't know if you remember the old Hagedorn Research Institute, but Novo actually had kind of like an academic research institute that was affiliated with us. And there was this group that were working on this glucagon tumor model that produced high levels of glucagon, GLP-1 and PYY. And these rats, they starved themselves to death. And I knew about that from 1994. So that actually inspired my thinking. So when Stephen Bloom's paper came out in January of 1996, and he was the first one to call GLP-1 a neurotransmitter, I think, but I was already way into actually screening these kind of molecules that later then became liraglutide.No One Else Thought About This [Obesity](04:54):And then I thought, why on earth should we not actually do both things at the same time? If we have an idea that can both work in diabetes in a much safer way than in insulin, and then also at the same time work in obesity. But the reality is that no one else thought about this, or if they thought about it, they didn't really think that it would a good idea. But I think I had the luxury of being in a biotech company, so everyone was working with peptides and proteins. So I don't think I got the same challenge that the other people in the other pharma's got when they all wanted small molecules.Eric Topol (05:36):Well, also just to set the foundation here, which you alluded to, there had been so many attempts to come up with a drug that would work, not just of course in diabetes where there are many classes of drugs, but moreover, to treat the condition of obesity. Actually, I was involved with one of them, Rimonabant and did the large trial, which as you know, led to having to stop the drug, discontinue it because it was associated with suicidal ideation and actual some suicide. So there had been such a long history of checkered inability to come up with a drug. But what was striking is the challenge, and this is one of the first important questions about, when you had the extended half-life of the first GLP-1 drug, that instead of having to take multiple times a day, you could actually, with liraglutide get to a point where you were starting to get to an extended half-life. This is now going back to 1997 with approval in 2010, still 14 years ago. But when you came up with this drug, because this was certainly one of your great contributions, this drug was just a step along the way in this kind of iterative process, wouldn't you say? It wasn't the long half-life and the potency that eventually got us to where we are today. Is that true?Lotte Bjerre Knudsen (07:15):Yeah, it was a stepwise process. And what's super interesting about this class of medicines is that they're actually so different. If you talk about a class of medicine where small molecules, they can be different, but they're usually more alike than they're different. And when it comes to this class with these medium-sized peptides, people tried a whole bunch of different things. So they're actually really, really different. Some are simple peptides. So the idea that I came up with was to use this fatty acid isolation principle, and that's then a subclass in the class. And then the first, once weekly, for example, was an antibody-based molecule liraglutide. So they're much, much, much larger molecule compared to the small peptides. So they're very different. And neither the simple peptides nor the really big antibody derived molecules, they don't give a lot of weight loss. So we actually get more weight loss with these kinds of molecules, which is also why you can now see that it has actually kind of inspired a whole industry to kind of try and go and make similar kinds of molecules.Eric Topol (08:27):Well, inspired a whole industry is an understatement. It's become the most extraordinary class of drugs, I think in medical history, having been a student of various, I mean obviously statins have been a major contribution, but this seems to have transcended that already. We're going to talk about more about where things are headed, but this fatty acid acetylation was a major step forward in extending the half-life of the drug, whereby today you can give semaglutide once a week. And this, I think, of course, there are many ways that you might've been able to extend the half-life, but you were starting with a hormone, a natural hormone neurotransmitter that had such an exquisitely short half-life of basically second or minutes rather than that you could give for a week. So I know there were many different ways you could have protected or extended the half-life one way or another, but this seemed to be a breakthrough of many along the chain of breakthroughs. But the question I have is when you were giving this to the diabetics, which was the precedent, that was really what these drugs were first intended, they didn't lose that much weight, and they never, still today when it's looked at for obese non-diabetics versus diabetics, there's a gap in weight loss. Why is that at the exact same dose, with the exact same peptide that the weight loss differs for people with type 2 diabetes as compared to those who have pure obesity?The Mystery of Why People With Type 2 Diabetes Don't Lose Weight Like Those With Obesity Lotte Bjerre Knudsen (10:09):Yeah, I can't give you a molecular answer to that, right. But I think the notion, I think it's the same for example with metformin, even though it gives less weight loss because that has also been tried in both people with diabetes and people without diabetes. So I think it's just for somehow people with diabetes are more resistant to weight loss. I think it's a really good question that I'm hoping maybe we could get through, for example, with proteomics and actually comparing people with diabetes and people without diabetes and looking at people who have the similar kind of weight loss. That could be really interesting. But I really don't have a good molecular answer for you, but it's just a really, really strong fact. But it also leads me to wanting to say it's interesting, because if that had been our motivation to actually say, oh, there's weight loss in diabetes, let's pursue it in people with obesity, I don't think we would've done that because the weight loss in people with diabetes wasn't that impressive. So it was very important for our chain of thought and decision early on that we actually knew that GLP-1 had these separate effects and that they could work in the brain and have a separate effect on well-known pathways in the brain. And that was more our motivation to actually continue to invest in obesity.Eric Topol (11:42):Yeah, no, I think this is when we did the research on the committee for the American Association for Advancement of Science (AAAS) award, the Mani L. Bhaumik Award, that you were recognized for the breakthrough of the year, this year. We tried to scour all the work and we actually had to hit Danish translations and all sorts of other papers they reviewed. And we learned through that process working on this committee that you were the one to be the champion of pushing this towards obesity, and it would've easily been missed because as we've been discussing, the weight loss in people with diabetes was small, but you push for it. And this was an extraordinarily important push because what it has resulted in, of course, has been spectacular. And obviously as we're going to get into much more than just obesity and obesity related conditions. But before we get to those other conditions, and as you've been known in the medical community as “the mother of GLP-1”, you were dubbed that term. The GLP-1 receptor is expressed in many parts of the body. Maybe you could just tell us about the distribution because this, I think is tied into these central nervous system effects that are not just related to the gut hormone type of axis.GLP-1 Receptors and the BrainLotte Bjerre Knudsen (13:17):So I spent a lot of time on that together with my amazing colleague, Charles Pyke, who's an histology expert because it turned out to be so very important. In general, when you're trying to make new medicines, understanding the mechanism, sometimes people say, yeah, who cares? But actually, it should matter, I think because where it becomes really important can be an understanding what they do not do. We've had to do a lot of proving the negatives for GLP-1. We went through these issues with thyroid cancer, pancreatitis, pancreas cancer. In all of that work, it was actually really important that we could show where the GLP-1 receptor was not expressed. So in the pancreas, we know that it's primarily on the insulin producing cells, and then we also have them in the intestine where they're probably involved in regulating inflammation and really creating a much healthier gut.(14:15):And then we have a lot of receptors in the brain. They're typically expressed on neurons, but they're also on astrocytes, they're also on smooth muscle cells. We have them on the heart and the sinus node. That's why there's a small increase in heart rate. We have them in the kidney, on again some smooth muscle cells that are renin positive. So there we can start thinking blood pressure and other things. So it turns out that you can go around the body and there are all of these specific GLP-1 receptor population, that you can see how they tie into the pharmacology. But obviously in physiology, they're not as important as they have turned out to be in pharmacology when we suddenly come with 24 hours a day exposure for a day or a week or for as long as the administration interval is. So, but specifically for obesity, I think it's in the vein, it's hard to, you should always be careful.(15:18):That's something I've learned to never say never. Of course, there could be a contribution from the peripheral nervous system as well to the effects in obesity. But I do think there are so many important and well described neuronal populations that have the GLP-1 receptor and which are accessible from the periphery. So just to mention, maybe one of the most, well-known is a POMC/CART neuron in the hypothalamus. They have the GLP-1 receptor, they're activated, but there also is an inhibitory tone on the AgRP and NPY neurons, and it fits very well with that. We know that people report that they feel more sated, they feel less hungry. But then there are also effects in the hindbrain and in some of the reward centers also have GLP-1 receptors. And we know that also now, we have really good actually clinical studies that show that there is a change in food choice and people can control their food intake better. So I think that fits very well with effects on the reward system. So it's a whole myriad, or maybe you could say that GLP-1 orchestrates a number of different neuronal populations to have these overall effects that reduce energy intake.Eric Topol (16:42):Yeah, it's pretty striking. It's almost like we're all walking around with GLP-1 deficiency, that if we had this present at higher levels around the clock, and of course eventually we'll see things that are well beyond obesity, how well this has an impact. Now, there was an extraordinary review in Cell Metabolism on the brain and GLP-1, and not just the brain, but the essential nervous system, the neurovascular, it's called the “GLP-1 programs and neurovascular landscape.”(17:20):And in this review, it got into the brain effects that were well beyond, I think what are generally appreciated. Not only the protection of the integrity of the blood-brain barrier, this whole neuroglial vascular unit, the myelin sheath protection, reducing inflammation within the brain, improving the glymphatic flow, which is of course critical for clearing waste and promoting cerebral vascular remodeling and more, so the brain effects here is what it seems to be. You mentioned the reward circuit, of course, but the brain effects here seem to be diverse, quite a bit of breath and extraordinary. And as we've seen in the clinic now with the work that's been done, we're seeing things about addiction, even gambling, alcohol, drugs, I mean neuropsychiatric impact, it's pretty profound. Maybe you could comment about that.On to Alzheimer's and Parkinson's DiseasesLotte Bjerre Knudsen (18:23):Yeah. I haven't read that paper yet, but I just saw it earlier. And I have been following this for about actually more than 10 years because when I was kind of over the big work of actually getting the approval for diabetes and obesity. I thought I had a little bit of capacity to actually look at Alzheimer's and Parkinson's disease because I just thought there's such an insane unmet need and what if GLP-1 could actually make a difference? And the first big paper that talked about this was actually in Nature Medicine in 2003, and it was originally, I think I should credit Nigel Greig. Greig, he's from NIH or from NIA, I can't remember, right. But he was actually the first one, I think to say if GLP-1 has all of these important effects in the pancreas and to protect cells, and there are all these GLP-1 receptors in the brain, maybe it also protects neurons.(19:25):So that was the first hypothesis. And the paper on Nature Medicine in 2003 describes how the GLP-1 receptor in the hippocampus is involved in cognition. And then we did a couple of studies in different animal models, and I was, to be honest, really confused. But then there was a new paper in Nature Medicine in 2018 that started to focus in on neuroinflammation. And by that time, I knew much more about inflammation and knew GLP-1 actually lower CRP by about 50% in the different trials. So I was really tuned into the potential importance of that in cardiovascular and kidney disease. But I was like, oh, what if that's also something that is important in the brain? Then it made more sense to me to try and build some evidence for that. So that was how we actually started looking at a hypothesis for Alzheimer's and Parkinson's.(20:21):And we now have a really large phase three study ongoing, but of course, it's a hypothesis, right? And no one has yet, I think, proven that GLP-1 has really important effects on these indications, but we are testing it in 4,000 people with Alzheimer's disease. So our hypothesis is around neuroinflammation, but defined in a way where you could say it's both peripheral inflammation and the effect it has on the vasculature, it's the effect on the blood-brain barrier. It's the astrocytes and the microglia, and there are probably also some T cells that have the GLP-1 receptor that could be important. And then couple that up also with some of the new information from neurons, because there are two papers to think in the last year that has highlighted neurons either in the hindbrain or a little bit further on. Both of them are probably hindbrain populations that actually seem to be really important in regulating both peripheral as well as central information.(21:27):So what if neurons are actually also an overlooked mechanism here, and both of these neuronal populations have the GLP-1 receptor and are accessible from the periphery, even though the child super paper in Nature doesn't mention that, but they do have the GLP-1 receptor. So there are all these different mechanisms that GLP-1 can have an impact on the broad definition maybe of neuroinflammation. And maybe the way one should start thinking about it is to say it's not an anti-inflammatory agent, but maybe it induces homeostasis in these systems. I think that could maybe be a good way to think about it, because I think saying that GLP-1 is anti-inflammatory, I think that that's wrong because that's more for agents that have a really strong effect on one particular inflammatory pathway.Eric Topol (22:22):That's a very important point you're making because I think we conceive of these drugs as anti-inflammatory agents from these more diverse actions that we've just been reviewing. But I like this restoring homeostasis. It's an interesting way to put it. This brings us, you mentioned about the Parkinson's, and when I reviewed the three randomized Parkinson's trials, they're all small, but it appears to be the first disease modifying drug ever in Parkinson's. Of course, these were done with different drugs that were older drugs. We haven't seen the ones that yet to be with semaglutide or other agents. And I wondered if you pushed, just like you did for obesity within Novo Nordisk, you pushed to go into obesity. Did you also force to push for Alzheimer's?Lotte Bjerre Knudsen (23:19):Yes. So that is also me who had to argue for that. I'm happy to do these things. I was born brave. I am happy to do these things.Eric Topol (23:31):That's wonderful. Without you, we would be way behind, and it took decades to get to this point. But look where we are now, especially with all the rigorous trials, the large clinical trials. You're into one right now of some 20,000 participants to see whether not just people with prior heart disease, but people without known heart disease to see whether or not this will have an effect. And there's so much data now, of course, already a completed trial with reduction of heart attacks and strokes. But now to extend this to people who are not such high risk, but these large trials, we keep learning more. Like for example, the reduction of inflammatory markers is occurring even before the weight loss that starts to manifest. So we learned a lot from the trials that are just even beyond some of the major primary outcomes. Would you agree about that?Lotte Bjerre Knudsen (24:34):So I'm not sure we can say that it comes before the weight loss because the energy intake reduction happens instantly. The glycemic response happens instantly. And all of these improvements will of course also have an effect to dampen inflammation. We do not have data that supports that it comes before because we haven't sampled that much in the beginning.Eric Topol (25:04):Okay.Lotte Bjerre Knudsen (25:05):I wouldn't be able to say that, and I don't think there are any, well, it's hard to keep up that the entire literature on GLP-1 these days, but I don't think anyone has actually shown that there is a separation because it's super hard to separate when things are occurring at the same time.Eric Topol (25:24):Yeah, I'm just citing the heart disease trial where in the New England Journal that point was made. But I think your point also that there was already a change in energy intake immediately is apropos for sure. Now, when we get into this new paper of yours, the proteomics, can you tell us about that because that's really exciting. We're in a high throughput proteomics era right now that we can analyze thousands of plasma proteins in any given individual. What are you learning about proteomics with the GLP-1 drug?The GLP-1 Drug Impact on ProteomicsLotte Bjerre Knudsen (26:07):Yeah, yeah. So I'm also the super excited about omics, right? Because I have worked in a wonderful organization of people who can do these large scale clinical trials, and we used to not collect a lot of samples for future use, but we've done that for some years now. So now we have this amazing collection of samples we can learn from and actually both inform the patients and the physicians, but also inform future research. So we have been doing that in our semaglutide trials, and we've just published the proteomics data from the step one and step two trials. So the phase 3a trials that supported the approval of semaglutide for the treatment of obesity. So one of them in people with obesity and one in people with obesity and diabetes, and those data are now published in Nature Medicine. [3 January 2025]. And we were learning a lot of things because you can compare the proteome effects to what has been done in the decode cohort.(27:11):So they have all these disease signature. So that's one thing that you can for sure see, and you can see a lot of things there with hints towards addiction. And then also you can take more predefined signatures also to look into what actually might be driving the cardiovascular risk. So I think there are so many things that you can learn from this, and of course it can also inform when you look at what's actually mediating the effect and probably something around inflammation is important. We have already also shown a more standard mediation analysis that shows that actually the most explainable factor for the effect on MACE [major adverse cardiovascular events] in the select trial is inflammation. It doesn't explain everything, but it actually looks like it's more important than BMI and weight loss. So that's really interesting how much we can learn from there. We're making the data are available at the summary statistic level so people can go and play with them ourselves.(28:23):And I think as we have more different kinds of medicines available in obesity, it's also a way to kind of compare how these different medicines work. And as we get more and more better at maybe also characterizing people with obesity, because I think that's a great thing that's going to happen now is there's going to be more funding for obesity research. Because I think that's what the attention that we are seeing right now is also giving. Then we can better start to understand. We always, we've been saying that people probably have different kinds of obesity, but we don't really know. So now we can actually start to understand that much better and maybe also understand how these different classes of medicines will work if we have the proteome data from different trials.Eric Topol (29:10):No, I'm absolutely fascinated about the proteomics. I call it a quiet revolution because many people don't know about it. [My recent post on this topic here.](29:18):The ability to assess thousands of proteins in each individual, and it's giving us new insights about cause and effect as you alluded to, the relationship with as you said, MACE (major adverse cardiovascular events) and the actions of this drug class. I mean, there's just so much we can learn here from the proteomics. Another thing that's fascinating about the GLP-1 is its effect on epigenetic clocks. And recently at one of the meetings it was presented, this is Steven Horvath that we had on Ground Truths not long ago. He talked about at this talk that for the first time to see that you could basically slow the epigenetic clock with a GLP-1. Is there any further information about that?Lotte Bjerre Knudsen (30:16):Yeah, no. We've never had enough of a sample size to actually be able to look at it, so unfortunately, no. But there is something else, right, because there is this group at the Stanford, Tony Wyss-Coray or something.Eric Topol (30:33):Yes, Tony Wyss-Coray.Lotte Bjerre Knudsen (30:35):Now he published a paper, is it two years ago? Where he did it using proteomics. He defined an anti-aging signature for various different organs.Lotte Bjerre Knudsen (30:46):We are in the process of trying to see if we could take those signatures and apply them on to our data.Eric Topol (30:55):Well, what's interesting is we're pretty close friends, and he, not only that paper you mentioned on organ clocks, which is a phenomenal contribution, but he has a paper coming out soon in Nature Medicine, the preprint is up, and what he showed was that the brain and the immune system was the main organ clocks that were associated with longevity. And so, it takes another step further and it's looking at 11,000 plasma proteins. So it's really interesting how this field is evolving because the omics, as you put it, whether it's proteomics, and now we're learning also about the epigenome and what brings us to the potential that this class of drugs would have an impact on health span in all people, not just those who are obese. Would you project that's going to be possible in the years ahead?Lotte Bjerre Knudsen (32:02):I don't know about health span, but because certainly there's been so many studies with metformin and there's been a lot of wonderful data showing an effect on the epigenetic clocks, but not really an effect on lifespan because that metformin is so widely used. If that was the case, it would be easy to dig those data out of different registries. But certainly a healthier aging is the most obvious one because when you have one class of medicine that actually has so many different effects. Right now we are looking at them at a one by one case, but we really should be looking at them so you are getting the benefits on the heart and the vasculature on the brain and the kidneys and the diabetes and the knees. You're getting all of that at the same time, and that certainly should lead to much, much healthier lives. And then of course, we just need to get people to eat healthier. Also, maybe we should talk a little bit about the food industry. I heard you did that in some of your podcast, right?Eric Topol (33:17):Yes. That is the big food, if you will. It's a big problem, a very big problem, and the ultra-processed foods. And so, lifestyle is not good and trying to compensate for that with a drug intervention strategy is like chasing your tail. So you're absolutely right about that. I mean, I guess what I'm getting into here is that whereas today we keep seeing the effects, whether it's the liver, the kidney, the heart, obesity, and people with diabetes. But for example, in the Alzheimer's trial, do you have to be obese to be enrolled in the Alzheimer's trial, or is it just people who are at risk for developingAlzheimer's?Lotte Bjerre Knudsen (34:01):Yeah, no, you do not have to be obese. It's a standard Alzheimer's trial.GLP-1 PillsEric Topol (34:07):So this will be one of the really important trials to get a readout in people who are not having an obesity background. Now, the future, of course, gets us to oral GLP-1 drugs, which obviously you have there at Novo Nordisk. And it seems to me once that happens, if it can simulate the effects we see with the injectables, that would be another big step forward. What do you think about that?Lotte Bjerre Knudsen (34:39):Yeah. Isn't it interesting, what we've learned is that people actually don't mind the injections, right? Also, because I think it's simple, once a week injection and the needles are so small, obviously there are people who really have needle phobia, but take those aside, it's relatively few. I would argue if you close your eyes and somebody else used this needle on you, you would not be able to feel where it was inserted, right? They're so small. So it becomes maybe a personal preference. Would you like to have once a day or maybe twice a day tablets, or are you fine with once a week injection? And I think there probably will be quite a few once they've tried it. And now so many have tried it and they actually, maybe it gives us a simple lifestyle. You don't have to do it every day, right? You can just have a weekly reminder.Eric Topol (35:46):Yeah, no, I think that's really interesting what you're bringing up. I never thought we would evolve to a point where injectables were becoming some common, and I even have some physician colleagues that are taking three different injectable drugs.Lotte Bjerre Knudsen (36:00):That's also just mentioned Richard DiMarchi, who I shared the Breakthrough Prize with, and also Svetlana Mojsov, who I was one of the other two recipients for the Lasker prize because they both been at Rockefeller, and they both have worked a lot with peptides, and they both say the same thing. They were told so many times, this is not medicines, these kinds of molecules just they're not medicines. Forget about it. It turns out people were wrong. And peptides can be medicines, and they can even be produced also in a sustainable manner with fermentation, which is not a bad way of producing medicines. And people actually don't mind. Maybe some people actually even like it because it's once a week and then it's done.Confronting BarriersEric Topol (36:58):Yeah, no, that's a very important point. And the quest for the oral, which have more issues with bioavailability versus the peptides that are having such pronounced impact is really interesting to ponder. Well, before we wrap up, it's very clear the impact you've had has been profound, not just obviously at Novo Nordisk, but for the world of advancing health and medicine. And you've mentioned some of the key other people who have made seminal contributions, but I think you stand out because when we went deep into who took this field forward into obesity and who might also wind up being credited for Alzheimer's, it was you. And as a woman in science, especially in an era that you've been at Novo now for three and a half decades, there weren't many women in science leaders. And for one to be, as you said, you're brave for the good old boys to listen to the woman in science. Tell us about that challenge. Was this ever an issue in your career? Because obviously we want to have this whole landscape change. It is in the midst of change, but it's certainly still a ways to go. So maybe you can give us insight about that.Lotte Bjerre Knudsen (38:27):Yeah. Well, it for sure was a thing. It was a very male dominated world, and in a way, it might have prevented other people from doing it. But then, as I said, I was born brave for some reason. I'm not really sure why. It actually motivated me to kind of like, yeah, I'm going to show them. I'm going to show them. So it never really got to me that people, not everyone was nice to say. There was the first 10 years of my career, I think they were quite lonely, but then I was really inspired. I was so happy to be allowed to work on this. I thought it was super fun. And I did find people who wanted to play with me. And I also have to say that the CSO back then, Mads Krogsgaard Thomsen, he always supported me. So maybe I didn't get everything I wanted, but I always got what I needed in order to progress.(39:29):So on the women's side, and I think that yes, and there's still a change to be made, and I'm actually a little bit on behalf of my generation, maybe not too proud of the change we made because we didn't do a lot of change. It was all the women coming from the arts and the culture. They were the ones who actually make the big change here like 5 or 10 years ago. So I've also started to be more open about sharing my journey and advocating for women in science. So that's why I show up in pink to some of these award sessions just to be a little bit different and to maybe also just show that you don't have to be a certain type in order to fit into a certain job. But there is still a change to be made where people should be better at listening to what a person say and what ideas they say.(40:28):And they should be mindful about not always labeling women as passionate. When people call me passionate, I say like, no, thank you. I'm actually not too happy about the mother of either, because men always are being told. They're being told that they're brave and ambitious and courageous and strategic, whereas we we're, oh, you're so passionate. No, thank you. I'm also brave and strategic and ambitious and all of that. So we simply put different vocabulary on. I don't think people don't do it on purpose. I think we need to be better at actually giving people at work the same kind of vocabulary for their contributions. And I think that would mean that we get listened to in the same way. And that would be important. And then I also have to say that science, whether it comes from men or women, doesn't really matter.(41:32):Successful science is always the work of many. And I hope that some of you will actually listen to my last speech because that's what I speak about, how it's always the work of the many. And also, how if you want to do something novel, then you actually have to do it at a time when no one else is doing it, and you should believe in your ideas. So believe in it, listen to the critique, but believe in it, and then come back with new arguments or give up if you can't come up with any new arguments, right?Eric Topol (42:05):Well, we'll definitely put a link to the Lasker Awards speech that you gave. And I just want to say that the parallels here, for example, with Kati Karikó , my friend who had the Nobel Award for mRNA, she spent three decades trying to get people to listen to her and never got a grant from the NIH or other places [our conversation here]. And it was a really tough battle. And as you already touched on Svetlana Mojsov, who did some of the seminal work at Rockefeller to isolate the portion of GLP-1, that really was the key part peptide, and it was overlooked for years. And so, it's a tough fight, but you're paving the way here. And I think the contributions you've made are just so extraordinary. And I hope that over the years we will continue to see this momentum because people like what you've done, deserve this extraordinary recognition. I'm glad to see. And the Lasker Award is really capping off some of that great recognition that is so well deserved. We've covered a lot of ground today, and I want to make sure if I missed anything that you wanted to get into before we wrap up.Lotte Bjerre Knudsen (43:30):I think we've been around all the exciting biology of GLP-1, both in diabetes, obesity, cardiovascular, kidney, potential in Alzheimer's and addiction. We'll see, we need the clinical data and we've put out a message to inspire people to do new science. There's still a lot of unmet need out there. There's a lot of diseases that don't have good treatments. Even in the diseases we've talked about there's a lot of money for diabetes. There are no disease modifying therapies for diabetes. It's not really changing the course of the disease. So there's a lot of things that needs great scientists.Eric Topol (44:17):And I guess just in finishing the discovery of this class of drugs and what it's led to, tells us something about that, there's so much more to learn that is, this has taken on perhaps the greatest obstacle in medicine, which was could you safely treat obesity and have a marked effect. Which decades, many decades were devoted to that and gotten nowhere. It's like a breakthrough in another way is that here you have an ability to triumph over such a frustrating target, just like we've seen with Alzheimer's, of course, which may actually intersect with Alzheimer's, with a graveyard of failed drugs. And the ones that it were approved so far in certain countries, like the US are so questionable as to the safety and efficacy. But it gives us an inspiration about what is natural that can be built on the basic science that can lead to with people like you who push within the right direction, give the right nudges and get the support you need, who knows what else is out there that we're going to be discovering in the years ahead. It's a broad type of lesson for us.Lotte Bjerre Knudsen (45:38):Yeah, there is another hormone that's also in phase three clinical development, right? The amylin hormone. We've had pramlintide on the market for years, but we have this long-acting version that is in phase three clinical development. That could be the same kind of story because there's also additional biology on that one.Eric Topol (45:58):Yeah, this is what grabs me Lotte, because these gut hormone, we've known about them, and there's several more out there, of course. And look what they're having. They're not just gut hormones, like you said, they're neurotransmitters and they're body-wide receptors waiting to be activated, so it's wild. It's just wild. And I'm so glad to have had this conversation with you. Now, congratulations on all that you've done, and I know the Nature Medicine paper that just came out is going to be just one of many more to come in your career. So what a joy to have the chance to visit with you, and we'll be following the work that you and your colleagues are doing with great interest.Lotte Bjerre Knudsen (46:45):And thank you very much, and thank you for your wonderful podcast. They're really great to listen to on the go. Very easy listening.*****************************************Please complete the quick poll question above.Thank you for reading, listening and subscribing to Ground Truths.If you found this podcast informative please share it!All content on Ground Truths—its newsletters, analyses, and podcasts, are free, open-access.Paid subscriptions are voluntary and of course appreciated. All proceeds from them go to support Scripps Research. Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. I welcome all comments from paid subscribers and will do my best to respond to each of them and any questions.Thanks to my producer Jessica Nguyen and to Sinjun Balabanoff for audio and video support at Scripps Research.Ground Truths now has subscribers in 203 countries! Get full access to Ground Truths at erictopol.substack.com/subscribe

In the fifth Season of the National Institute of Neurological Disorders and Stroke's Building Up the Nerve podcast, we help you strengthen your science communication skills with tools and advice to use throughout your career. We know that navigating your career can be daunting, but we're here to help—it's our job!In the fifth episode of the season, we talk about Securing Funding for Research focusing on choosing what funding to apply for, “pitching” your science to different funders, and writing effective grant applications.Featuring Sonya Dumanis, PhD, Executive Vice President of the Coalition for Aligning Science and Deputy Director for Aligning Science Across Parkinson's; Kat M. Steele, PhD, Associate Director of CREATE and Albert Kobayashi Professor in Mechanical Engineering at University of Washington; and Gene Yeo, PhD, MBA, Professor of Cellular and Molecular Medicine at University of California, San Diego and Chief Scientific Advisor, Sanford Laboratories for Innovative Medicine.ResourcesNIH Funding OpportunitiesSmall Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants: https://seed.nih.gov/small-business-funding/small-business-program-basics/understanding-sbir-sttr NINDS Funding Opportunities: https://www.ninds.nih.gov/funding/find-funding-opportunities NINDS Training & Career Development Opportunities: https://www.ninds.nih.gov/funding/training-career-development NIH ResourcesEarly Career Reviewer program: https://public.csr.nih.gov/ForReviewers/BecomeAReviewer/ECR NIH RePORTER: https://reporter.nih.gov/ Early Stage Investigator (ESI) Policies: https://grants.nih.gov/policy-and-compliance/policy-topics/early-stage-investigators NINDS Guidelines for incorporating rigor into grant applications: https://www.ninds.nih.gov/funding/preparing-your-application/preparing-research-plan/rigorous-study-design-and-transparent-reporting NIH Activity Codes: https://grants.nih.gov/funding/activity-codes Allen Institute's Allen Distinguished Investigators: https://alleninstitute.org/division/frontiers-group/distinguished-investigators/ Advanced Research Projects Agency for Health (ARPA-H): https://arpa-h.gov/ Aligning Science Across Parkinson's (ASAP) Disease – Collaborative Research Network (CRN): https://parkinsonsroadmap.org/research-network/# California Institute for Regenerative Medicine (CIRM) grants: https://www.cirm.ca.gov/ Transcript available at http://ninds.buzzsprout.com/.

More than a million pounds is being given by the Government to the Food Standards Agency, to decide what needs to be put in place to ensure new, "cell-cultivated" foodstuffs will be safe to eat. We hear from the FSA's Chief Scientific Advisor.The long-running case about whether the public can 'wild camp' on Dartmoor, will be heard in the Supreme Court, where a final determination will be made. The dispute is between Dartmoor National Park and landowners Alexander and Diana Darwall, who own Stall Moor common on south-west Dartmoor.It's one year since the launch of the Welsh Government's Natural Flood Management Accelerator programme - a 2-year, £4.6 million investment in nature-based solutions to reduce flooding. We visit one of the 23 projects.And people living in a small coastal community near Robin's Hood Bay in North Yorkshire say they fear being cut off this winter, after a landslip caused the closure of the only road in and out of their village. It's not yet known when the road will be fixed. In the meantime the council has set up an alternative route - a 12 mile diversion via a former railway line - but, locals say it's unsuitable and potentially unsafe during the winter months.Presented by Anna Hill Produced by Heather Simons

The world of quantum technology is not some science fiction flight of fantasy, it is an exciting field of science which is turning into a rapidly growing engineering sector. You might not know it but you can already buy quantum-dot TVs and mobile phones with quantum-enhanced encryption. Quantum technologies are poised to expand the realm of engineering in ways that were unthinkable until just a decade ago.         Dr Elizabeth Eso aligning an optical system to experimentally demonstrate a time-bin quantum key distribution system. Credit: Chris Watt Photography   Quantum engineering is the development of technology that exploits the laws of quantum mechanics (the behaviour of nature at and below the scale of atoms), using it as a toolbox for the development of quantum technologies, such as quantum sensors or quantum computers. There are many devices available which rely on quantum mechanical effects such as medicine, optical communication, high-speed internet, and high-performance computing, just to mention a few examples.       An IBM engineer adjusting on one of the company's quantum computers. Credit: Connie Zhou for IBM   After the technological advances that brought us lasers, MRI imagers and transistors, a second wave of quantum technologies is expected to impact society in a similar way. These new technologies will make use of quantum coherence (the regular and predictable behaviour of atoms), building on the progress achieved in the last century, to enable us to have greater control of these atomic-scale systems.   The burgeoning quantum industry requires a quantum-literate workforce; something that is in short supply at the moment. Those working in the field mainly come from either a physics or engineering background and have acquired their ”quantum engineering skills” by experience. Many of the companies that could benefit from quantum technologies already have a strong presence here in the UK, including those involved in new materials, pharmaceuticals, chemicals, energy, aerospace, defence and financial services, but what other application will we as engineers be able to use quantum technologies for?       An IBM engineer working on the refrigerator casing inside of which the company plans to install a 1 million-qubit quantum computer by 2030. Credit: Connie Zhou for IBM.   Helen's Guests are Tobias Lindstrom, Head of Science for the department of Quantum Technology at the National Physical Laboratory and Sir Peter Knight, Professor of Quantum Optics and Senior Research Investigator at Imperial College London, and principal of the Kavli Royal Society International Centre.   Tobias received his PhD in Physics from Chalmers University of Technology, Sweden, before joining NPL as a Senior Scientist , then Principal Scientist and now head of department. During his time at NPL, Tobias has primarily worked on superconducting quantum technology.  In addition to conducting research relevant for the emerging superconducting quantum computing sector, he has also pioneered the use of precision frequency metrology methods for the study of noise in superconducting resonators and qubits. Tobias is also part of a global effort to develop international standards for quantum technologies.   Sir Peter is a leading academic in the field of quantum optics and has been described as "one of the UK's most influential scientists and leaders of scientific policy" by his peers. He has been the recipient of several major awards including the Royal Medal from the Royal Society and the Thomas Young Medal from the Institute of Physics. Sir Peter was President of the Institute of Physics from 2011 to 2013 and of Optica; The Optical Society of America and is also a Fellow of the Royal Society. He was also Chief Scientific Advisor until his retirement to the National Physical Laboratory and is Chair of NPL's Quantum Metrology Institute. He continues to act as an advisor to the British government.   Useful Links: NPL Quantum Technologies Quantum Computing & Simulation Hub  Bristol University - What is Quantum Engineering?     We would love to hear your thoughts and comments on this episode. If you would like to get in touch, email us at podcast@imeche.org You can find more information about the work of the IMechE at www.imeche.org 

I'm delaying the follow up to last week's piece on sleep for another week because I am still experimenting ;). In the meantime, I hope today's little story will put a smile on your face.And a reminder there are just a handful of tickets left for my “lecture with funny bits” at the Museum of Comedy on October 10th - October 9th was cancelled - sorry. This is a super interesting show, even though I say so myself. If you are free, I really recommend it.In 1914, a young German named Heinz Kurschildgen started his first job as an apprentice in a dye factory in his hometown of Hilden. He became fascinated by the chemicals he was working with, and built a small laboratory at home to conduct experiments.Before long, he thought he had found a way to make gold, and even persuaded several investors to give him money. However, it soon became clear that he couldn't make gold and found himself prosecuted for fraud. The courts let him off on the grounds that mentally he was not all there, but only on condition that he solicited no further investments with schemes to make gold. He was soon claiming he could make other transmutations, and became something of a joke figure in his hometown, where a bust was even erected in his honour, albeit ironically, inscribed with the words: “For the genius gold-maker, from his grateful hometown.”But in 1929, he returned to his first calling, which was kidding people he could make gold. He approached German President Paul von Hindenburg and Head of the Reichsbank, Hjalmar Schacht, with a proposal to make the gold they needed to pay off Germany's WWI reparations.These had been set at 132 billion gold marks, which translates to 47,300 tonnes. To give you an idea how unrealistic a figure this was: it was an amount not far off all the gold that had ever been mined in history by that time. That would take quite some alchemy.But Kurschildgen was not a man to be deterred. He raised a load more money, defrauded his clients, and ended up with another 18 months in jail.You really should subscribe to this wonderful publication.After his release, he was soon at it again. This time, he approached the newly elected Nazi government with a plan to make petrol from water. Chief Scientific Advisor, Wilhelm Keppler, paid him a visit and Kurschildgen agreed to reveal his methods and surrender the rights to the government. Meanwhile, his claims about being able to make gold piqued the interest of SS leader Heinrich Himmler, who had a notoriously superstitious streak and a fascination with alchemy. Himmler started generously funding Kurschildgen to conduct his experiments. But Reichsanstalt physicists soon declared his contraptions useless, and Kurschildgen ended up in a concentration camp.“Himmler has fallen for a gold and petrol maker,” said Joseph Goebbels in his dairy. “He wanted to defraud me, too. I knew what he was about straight away”.After two years Kurschildgen was released for good behaviour. Himmler had him put straight back in the camp. On no account did he want this embarrassing story becoming public.After the war, Kurschildgen tried to get recognized as a victim of Nazi persecution, so he could claim compensation. “The Gestapo would stop at nothing to get my invention," he told the courts. As with most of his ventures, his petition was unsuccessful.Even so, you can't fault the man's ambition.Until next time,PS Don't forget Shaping the Earth on October 10th.If you are interested in buying actual gold in these uncertain times, then look no further than my recommended bullion dealer, the Pure Gold Company. Premiums are low, quality of service is high, and you get to deal with a human being who does not moonlight as an alchemist! This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.theflyingfrisby.com/subscribe

I'm delaying the follow up to last week's piece on sleep for another week because I am still experimenting ;). In the meantime, I hope today's little story will put a smile on your face.And a reminder there are just a handful of tickets left for my “lecture with funny bits” at the Museum of Comedy on October 10th - October 9th was cancelled - sorry. This is a super interesting show, even though I say so myself. If you are free, I really recommend it.In 1914, a young German named Heinz Kurschildgen started his first job as an apprentice in a dye factory in his hometown of Hilden. He became fascinated by the chemicals he was working with, and built a small laboratory at home to conduct experiments.Before long, he thought he had found a way to make gold, and even persuaded several investors to give him money. However, it soon became clear that he couldn't make gold and found himself prosecuted for fraud. The courts let him off on the grounds that mentally he was not all there, but only on condition that he solicited no further investments with schemes to make gold. He was soon claiming he could make other transmutations, and became something of a joke figure in his hometown, where a bust was even erected in his honour, albeit ironically, inscribed with the words: “For the genius gold-maker, from his grateful hometown.”But in 1929, he returned to his first calling, which was kidding people he could make gold. He approached German President Paul von Hindenburg and Head of the Reichsbank, Hjalmar Schacht, with a proposal to make the gold they needed to pay off Germany's WWI reparations.These had been set at 132 billion gold marks, which translates to 47,300 tonnes. To give you an idea how unrealistic a figure this was: it was an amount not far off all the gold that had ever been mined in history by that time. That would take quite some alchemy.But Kurschildgen was not a man to be deterred. He raised a load more money, defrauded his clients, and ended up with another 18 months in jail.You really should subscribe to this wonderful publication.After his release, he was soon at it again. This time, he approached the newly elected Nazi government with a plan to make petrol from water. Chief Scientific Advisor, Wilhelm Keppler, paid him a visit and Kurschildgen agreed to reveal his methods and surrender the rights to the government. Meanwhile, his claims about being able to make gold piqued the interest of SS leader Heinrich Himmler, who had a notoriously superstitious streak and a fascination with alchemy. Himmler started generously funding Kurschildgen to conduct his experiments. But Reichsanstalt physicists soon declared his contraptions useless, and Kurschildgen ended up in a concentration camp.“Himmler has fallen for a gold and petrol maker,” said Joseph Goebbels in his dairy. “He wanted to defraud me, too. I knew what he was about straight away”.After two years Kurschildgen was released for good behaviour. Himmler had him put straight back in the camp. On no account did he want this embarrassing story becoming public.After the war, Kurschildgen tried to get recognized as a victim of Nazi persecution, so he could claim compensation. “The Gestapo would stop at nothing to get my invention," he told the courts. As with most of his ventures, his petition was unsuccessful.Even so, you can't fault the man's ambition.Until next time,PS Don't forget Shaping the Earth on October 10th.If you are interested in buying actual gold in these uncertain times, then look no further than my recommended bullion dealer, the Pure Gold Company. Premiums are low, quality of service is high, and you get to deal with a human being who does not moonlight as an alchemist! This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.theflyingfrisby.com/subscribe

From aerospace engineering to being a leading voice of Responsible A.I., meet Dr. Kelly Cohen. Dr. Cohen is the Brian H. Rowe Endowed Chair in Aerospace Engineering and Professor of Biomedical Engineering at the University of Cincinnati. With over three decades of experience in Fuzzy Logic systems research, Dr. Cohen has advanced Explainable A.I. from autonomous robotics to personalized medicine.  His work has earned him the presidency of the North American Fuzzy Information Processing Society and grants from NSF, NIH, USAF, and NASA. He's also co-founded Genexia and serves as Chief Scientific Advisor for BrandRank.ai, bridging academia and industry in the pursuit of ethical, transparent A.I. systems. Dr. Cohen is also our organizing partner for CincyAI for Humans, the largest A.I. meetup in all of Ohio that I co-host with Kendra Ramirez. CincyAI takes place every month at the University of Cincinnati's Digital Futures building which is an interdisciplinary research facility home to globally recognized leading research in responsible A.I., including Dr. Cohen's lab. As A.I. rapidly integrates into every aspect of our lives, Dr. Cohen's focus on responsible development couldn't be more timely or critical. In today's conversation, you'll hear Dr. Cohen's insights on the current state of A.I., the importance of Responsible A.I. development, and his vision for a future where A.I. enhances human capabilities without compromising ethics. We'll discuss his work in testing and verifying A.I. systems, the exciting developments happening at the University of Cincinnati, and why he believes that being responsible with A.I. doesn't mean sacrificing innovation. Dr. Cohen's enthusiasm for Responsible A.I. and his commitment to making the world a better place through technology is truly infectious. Join us as we explore the intersection of A.I., ethics, and human potential with one of the field's most passionate and knowledgeable voices.  EPISODE SHOW NOTES: *COMING SOON* JOIN CREATIVITY SQUARED Sign up for our free weekly newsletter: https://creativitysquared.com/newsletter  Become a premium member: https://creativitysquared.com/supporters  SUBSCRIBE Subscribe on your favorite podcast platform: https://creativitysquared.com Subscribe for more videos: https://youtube.com/@creativity_squared/?sub_confirmation=1 CONNECT with C^2 https://instagram.com/creativitysquaredpodcast https://facebook.com/CreativitySquaredPodcast https://giphy.com/channel/CreativitySquared https://tumblr.com/blog/creativitysquared https://tiktok.com/@creativitysquaredpodcast #CreativitySquared CONNECT with Helen Todd, the human behind C^2 https://instagram.com/helenstravels https://twitter.com/helenstravels https://linkedin.com/in/helentodd https://pinterest.com/helentodd Creativity Squared explores how creatives are collaborating with artificial intelligence in your inbox, on YouTube, and on your preferred podcast platform.  Because it's important to support artists, 10% of all revenue Creativity Squared generates will go to ArtsWave, a nationally recognized non-profit that supports over 100 arts organizations. This show is produced and made possible by the team at PLAY Audio Agency: https://playaudioagency.com. Creativity Squared is brought to you by Sociality Squared, a social media agency who understands the magic of bringing people together around what they value and love: http://socialitysquared.com.  #NextLivesHere #universityofcincinnati #digitalfutures #OhioX #ResponsibleAI #DigitalCreativity #FutureTechnology #FutureTech #CincyAI #DeepLearning #GenerativeModels #ConversationalAgents #AINews #AIAdoption #ArtificialIntelligenceAI #TechPodcast #AIPodcast #AIArt #DigitalEthics #AIAwareness #AIResponsibility #EthicalDevelopment #TechInnovation #AILearning #EthicalInsights #AIandSociety

Dr. Daniel Vigo, B.C.'s chief scientific advisor for psychiatry, toxic drugs and concurrent disorders, discusses how the Mental Health Act will be used for the province's involuntary treatment plan.Then, Bif Naked joins us to talk about returning to life on the road for her new album Champion, and what it means to be a Canadian rock icon. We take your calls to hear your favourite Bif Naked memories and to speak to Bif herself!

In this episode, SMA Tilley sits down with Dr. Katy Dondanville, Clinical Psychologist at UT Health San Antonio and Chief Scientific Advisor for Face the Fight in the second of a series of episodes recognizing National Suicide Prevention Month. Dr. Dondanville shares important information on the organization's quest to break the stigma surrounding suicide in the military community, reduce Veteran suicide, and the many resources and treatments available for Veterans and their Families.

In this episode, you'll get to explore the fascinating world of quantum energy with Philipp von Holtzendorff-Fehling, the visionary founder of Leela Quantum Tech, and Chief Scientific Advisor, Ian Mitchell. Additionally, you'll discover how quantum fluctuations in water could be powering your cells, and why shielding yourself from electromagnetic frequencies might be the missing link to optimal health. We'll also dive into quantum tech applications that go beyond the ordinary, from enhancing your food to innovative wearables like charged underwear. You'll uncover the science behind these breakthroughs, backed by rigorous studies, learn about the remarkable healing effects that could revolutionize your well-being, and much more! Whether you're a curious skeptic or a quantum believer, this episode is designed to elevate your understanding of how quantum energy can optimize your body, mind, and spirit. Tune in, and prepare to rethink everything you thought you knew about energy and health. Full show notes: https://bengreenfieldlife.com/quantumquestions Episode Sponsors:  Pendulum: You get 20% off your first month of any Pendulum probiotic with code GREENFIELD at PendulumLife.com/Greenfield. SiPhox: Visit siphox.health/ben with code BEN to get 10% off your health kit! LVLUP Health: Head over to lvluphealth.com/BGL for a special discount on their game-changing range of products. MUDWTR: Adaptogens, antioxidants, 100% USDA-certified organic, non-GMO, gluten-free, vegan and kosher. Up to 43% off & free shipping mudwtr.com/bengreenfield. Apollo: Head over to apolloneuro.com/bengreenfield and use code BG15 for 15% off.See omnystudio.com/listener for privacy information.

Our first guest of this season, Dr. Karaitiana Tairu, joins us for an insightful discussion on the intersection of AI and the Pacific Islands. Dr. Tairu discusses the intricate balance between preserving cultural heritage and embracing innovation, highlighting the role of AI in creating sustainable solutions tailored to the unique needs of the Pacific Islands. This episode is a must-listen for anyone interested in the convergence of tradition and technology About AI Asia Pacific Institute The AI Asia Pacific Institute (AIAPI) is a global not-for-profit committed to strengthening the Asia-Pacific economies by facilitating the responsible development and adoption of artificial intelligence. The AIAPI serves as an independent catalyst, uniting stakeholders to guide AI's responsible development through interdisciplinary research, awareness raising, international collaboration, and policy advisory activities. About Dr Karaitiana Taiuru Dr Taiuru is a leading authority and a highly accomplished visionary Māori technology ethicist specialising in Māori rights with AI, Māori Data Sovereignty and Governance with emerging digital technologies and biological sciences. He brings extensive expertise in mātauranga, tikanga Māori, te Tiriti and advocacy for digital Māori rights and a profound understanding of the intersection between Māori knowledge and emerging technologies. A professional director with membership with Institute of Directors, with roles including membership and Kahui Māori advisor of the New Zealand AI Forum, member and tangata whenua governor of the AI Researchers Association, invited member of the Expert panel on AI and healthcare for the Office of the Prime Minister's Chief Scientific Advisor, a legislated expert member of the Intellectual Property Office (IPONZ) Trade Marks Advisory Committee and Ministry of Health Tikanga Expert on Assisted Reproduction, as well as many other governance appointments.

Subscribe to our channel: https://www.youtube.com/@optispan Check out the Brenner lab: https://brennerlab.net Related episodes: The Benefits of Protein Restriction, How Protein Affects Hormones & FGF21: https://youtu.be/Nf1GhkAFiWY Matt and City of Hope Alfred E. Mann Family Foundation Chair of Diabetes and Cancer Metabolism Charles Brenner have had several public disagreements on social media. We love a good conversation between two distinguished scientists whose views may not entirely align, so we were pleased to host Charles on the Optispan Podcast for a discussion of topics in geroscience ranging from whether sirtuins are actually longevity regulators to the clinical utility of epigenetic age tests to the incentive structures around clinical trials. We also spent a chunk of time on NAD+ boosters, one of Charles' areas of expertise, and their relevance to aging and other conditions such as COVID-19. Prior to his City of Hope appointment, Charles served on the faculties of Thomas Jefferson University, Dartmouth College, and the University of Iowa, where he was the Roy J. Carver Head of Biochemistry for 11 years. He currently serves as the Chief Scientific Advisor of the biotechnology company ChromaDex, which uses his nicotinamide riboside (NR) intellectual property. He is also a cofounder of biotechnology companies Alphina and Juvenis. Charles conducted postdoctoral research at Brandeis University and received a PhD and a B.A. from Stanford University and Wesleyan University respectively. Producers: Tara Mei, Nicholas Arapis Video Editor: Jacob Keliikoa DISCLAIMER: The information provided on the Optispan podcast is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices. More places to find us: Twitter: https://twitter.com/optispanpodcast Twitter: https://twitter.com/optispan Twitter: https://twitter.com/mkaeberlein Linkedin: https://www.linkedin.com/company/optispan https://www.optispan.life/

We were extremely pleased to interview Dr. Paul Alexander who is the Chief Scientific Advisor for The Wellness Company from Canada. He graduated from Oxford University, McMaster University and the University of Toronto. He was also senior advisor to the W.H.O. and senior advisor to the Trump administration reporting directly to the Oval office in 2020.Carl's first question to him is, “as a lead scientist, how did you feel about knowing the ‘virus' was never isolated, making a vaccine absolutely impossible.Bryan and Carl were astounded hearing from a scientist who had to battle daily with Fauci and Burkes, while presenting faux facts to the POTUS. The truth is NO SCIENCE was involved with their declarations of masking and social distancing which were completely made up as admitted by an insider and more recently came out in Fauci's interrogation before Congress.It is mind numbing to consider the millions of lives/businesses that were laid waste by these draconian assertions to say nothing of the many suicides committed by the hopeless masses.Going back to some early dark projects in 1962 that the DOJ presented to President Kennedy (who rejected them at that time) reveals a faction of the Government that is completely ruthless and single minded about achieving control.He details how Trump was surrounded by people who were plotting against him at every step. Quite the ride! Join us for an exhilarating and timely discussion as we go into the next four months of crazy town before the all important next election.Subscribe to Freedom First Network on Rumble to watch all of our shows LIVE: https://freedomfirst.tvBe ready for anything life throws your way with The Wellness Company's Medical Emergency Kit. Order today using code CARL for a 10% discount at https://twc.health/ffn.Elevate your meals with Freedom First Beef… even if you find yourself in the middle of the apocalypse! Use code CARL for 15% off and enjoy high-quality beef whenever you crave it – today or tomorrow! https://freedomfirstbeef.comJoin the ranks of the wise who secure their assets against government overreach and economic instability, with their 3-step, tax-free process for setting up your Gold IRA. Click here to get their FREE Gold and Silver Guide. https://pickaxgold.comUnleash the spirit of liberty in every cup with Freedom First Coffee's Founders Blend. Order now using code CARL and savor the unparalleled taste of freedom in every patriotic sip. https://freedomfirstcoffee.com

Join Dr. Leigh Richardson on this enlightening episode of In Your Head with Dr. Leigh Richardson, featuring a special conversation with Dr. Katy Dondanville. As the Chief Scientific Advisor for USAA's Face the Fight Initiative, Dr. Dondanville shares compelling insights into the collaborative efforts of corporations, foundations, non-profits, and veteran-focused organizations to combat veteran suicide. This powerful coalition is dedicated to raising awareness and fostering support for a cause that touches us all—preventing veteran suicide. During the podcast, Dr. Dondanville unveils common myths surrounding veteran suicide and stresses the critical importance of mindful language to promote safety and prevent harm. She highlights the initiative's commitment to firearm safety, including the creation of secure storage spaces for firearms before they become a crisis tool. Face the Fight aims to significantly reduce veteran suicide rates over the next decade, and Dr. Dondanville's expertise guides this pivotal movement. Tune in to gain a deeper understanding of the resources available to veterans and their families and learn how each of us can contribute to this vital cause. After the podcast, visit The Brain Performance Center's website at https://thebrainperformancecenter.com/ to explore how our programs can support individual brain health needs. Whether you're seeking advice or a comprehensive consultation, our dedicated team is ready to help you achieve optimal brain performance. Phone: 214-329-9017 Email: info@thebrainperformanceinstitute.co Listen to In Your Head with Dr. Leigh Richardson wherever you get your podcasts, and join us in supporting our veterans through education, awareness, and actionable initiatives.

Episode #1025 Presidential Takedown - How Fauci, the CDC and the WHO Conspired to Overthrow Trump Richard speaks with Dr. Paul Elias Alexander, former Senior Advisor to COVID Pandemic policy in the US government for President Trump and former COVID Pandemic evidence-synthesis advisor to WHO-PAHO. Dr. Alexander was on the frontlines to watch how Trump's world, and his reelection hopes, slowly collapsed leading up to November 2020—due to the CDC, NIH, and WHO conspiring to overthrow him with the worst response possible to the COVID crisis. GUEST: Dr. Paul Alexander is the Chief Scientific Advisor at The Wellness Company Canada. He graduated from Oxford University, McMaster University, and the University of Toronto. He was also a senior advisor to the W.H.O and senior pandemic advisor to the Trump administration reporting directly to the oval office in 2020. Today, Dr. Alexander supports many global groups as theyrelate to the COVID pandemic and is focused on overall health and wellness as our society recovers and moves forward. WEBSITES: https://www.twc.health/liberty BOOK: Presidential Takedown: How Anthony Fauci, the CDC, NIH, and the WHO Conspired to Overthrow President Trump SUPPORT OUR SPONSORS!!! BIRCH GOLD GROUP - The Precious Metal IRA Specialists Diversify a portion of your savings into GOLD with Birch Gold Group. Gold is your hedge against inflation, and Birch Gold makes it EASY to own. Text STRANGE to 989898 and get your free info-kit on gold, then talk to a precious metals specialist on how to protect your savings from persistent inflation with gold. Text STRANGE to 989898 now. BECOME A PREMIUM SUBSCRIBER!!! https://strangeplanet.supportingcast.fm Three monthly subscriptions to choose from. Commercial Free Listening, Bonus Episodes and a Subscription to my monthly newsletter, InnerSanctum. Visit Use the discount code "Planet" to receive one month off the first subscription. We and our partners use cookies to personalize your experience, to show you ads based on your interests, and for measurement and analytics purposes. By using our website and services, you agree to our use of cookies as described in our Cookie Policy. Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://strangeplanet.supportingcast.fm/

On our Novo Nordisk episode, we covered the business of Ozempic, the GLP-1 taking the world by storm. On this episode, we dive into the science of the molecule semaglutide (and its predecessor liraglutide) with the world expert on the topic, Lotte Bjerre Knudsen. Lotte is Novo Nordisk's Chief Scientific Advisor, and led the research group back in the early 1990s that first invented the molecule. A few topics from our conversation:The science behind what is happening in the body that causes weight loss while on OzempicWhat it was like in the 1990s and 2000s believing in a drug for a problem that the rest of the industry (including her own company) had written offHow weight loss was actually a goal from the very start — not just a side effect of diabetes medication like you often read today!Sponsors:Quartr

The Richard Syrett Show, February 23rd, 2024 Toronto Raptor Fans Wearing Hoodies Adorned with Star of David and "Free Our Hostages" Asked to Leave ScotiaBank Arena - Joe Warmington, Toronto Sun columnist Poilievre condemns Liberals' online harms bill as assault on free speech - Isaac Lamoureux, True North Trump's Pandemic Advisor Says Covid Vaccine Appears to be Depopulation Weapon - Dr. Paul Alexander, Chief Scientific Advisor at The Wellness Company Canada https://www.twc.health/liberty Talkin' Trout - Mike Karafilidis, Play-by-Play Announcer for The Mississauga Steelheads Previews This Weekend's Action in the Ontario Hockey League President of College at centre of Women's Volleyball Game Featuring Five Biological Male Players Issues Statement Condemning Rebel News Coverage of Game - David Menzies, Rebel News Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Paul Alexander is the Chief Scientific Advisor at The Wellness Company Canada. He graduated from Oxford University, McMaster University, and the University of Toronto. He was also a senior advisor to the W.H.O. and senior pandemic advisor to the Trump administration reporting directly to the oval office in 2020. Today, Dr. Alexander supports many global groups as they relate to the COVID pandemic and is focused on overall health and wellness as our society recovers and moves forward. You can find Dr. Alexander at drpaulalexander.com or on his substack at https://substack.com/@drpaulalexander---GET IN TOUCH:---Follow me on IG, X, and TikTok at @iamdavehurt. For business inquiries and booking info email dave@justworkco.com--WORK WITH ME:---$150 Consultation Call, Custom Nutrition Plan, Custom Training Program, and Custom Supplement Plan: https://calendly.com/freemindpodcast/...---Book a Free Consultation for my 1-on-1 Training & Nutrition Coaching: https://calendly.com/freemindpodcast/...SUPPORT OUR SPONSORS:---Thank you to our sponsor The Wellness Company for making this interview possible. Use the link www.twc.health/freemind to get a discount on their amazing products and services.---Get the BEST nutritional supplements on the market & enjoy perks like FREE shipping & a FREE month of access to certified trainers & nutritionists through the 1P app: www.1stphorm.com/hurt ---Get a discount on the BEST natural, non-synthetic GH alternative: www.bioproteintech.com use code “freemind”---Purchase our apparel at www.justworkco.co ---Use code HURT at www.upfreshkitchen.com for a discount on their delicious prepared meals

Dr. Paul Alexander is the Chief Scientific Advisor at The Wellness Company Canada. He graduated from Oxford University, McMaster University, and the University of Toronto. He was also a senior advisor to the W.H.O. and senior pandemic advisor to the Trump administration reporting directly to the oval office in 2020. Today, Dr. Alexander supports many global groups as they relate to the COVID pandemic and is focused on overall health and wellness as our society recovers and moves forward. You can find Dr. Alexander at drpaulalexander.com or on his substack at https://substack.com/@drpaulalexander---GET IN TOUCH:---Follow me on IG, X, and TikTok at @iamdavehurt. For business inquiries and booking info email dave@justworkco.com--WORK WITH ME:---$150 Consultation Call, Custom Nutrition Plan, Custom Training Program, and Custom Supplement Plan: https://calendly.com/freemindpodcast/...---Book a Free Consultation for my 1-on-1 Training & Nutrition Coaching: https://calendly.com/freemindpodcast/...SUPPORT OUR SPONSORS:---Thank you to our sponsor The Wellness Company for making this interview possible. Use the link www.twc.health/freemind to get a discount on their amazing products and services.---Get the BEST nutritional supplements on the market & enjoy perks like FREE shipping & a FREE month of access to certified trainers & nutritionists through the 1P app: www.1stphorm.com/hurt ---Get a discount on the BEST natural, non-synthetic GH alternative: www.bioproteintech.com use code “freemind”---Purchase our apparel at www.justworkco.co ---Use code HURT at www.upfreshkitchen.com for a discount on their delicious prepared meals

PART 6. Dr. Paul Alexander is the Chief Scientific Advisor at The Wellness Company, and a former Trump administration official at the U.S. Department of Health and Human Services (HHS) during the COVID-19 pandemic.

Julie Williams has dedicated much of her career to uncovering the genetic signposts for the most common cause of dementia: Alzheimer's disease. Chris Smith caught up with her to hear about influences she had growing up, how a revolution in genetics means we could be on the verge of key breakthroughs in fighting neurodegenerative conditions, and speaks about her time as Chief Scientific Advisor for Wales... Like this podcast? Please help us by supporting the Naked Scientists

“As you grow older, your brain is able to keep rewiring all the time. And so we have this impression that the flexibility of the brain decreases as you get older. But in fact, it's just because your brain's job is just to figure out how to get by in the world and do a good job in the world. And once you've figured most things out, like, oh, these are different kinds of personalities, and this is how I need to do something at work, and this is how I use email and phone and whatever, then your brain does less changing only because it has successfully done its job, and it doesn't need to keep changing. The brain changes when there's surprise, when there's something that happened that it wasn't expecting, then it changes up. So, you still have plenty of plasticity even when you're 90 years old. It's just that most people aren't using it at that point because they say, Oh, I got it. I know how things work.” So says David Eagleman, renowned neuroscientist, podcast host, and the author of many bestselling books about consciousness and the brain—along with more than 120 academic publications. Besides his perch as a neuroscientist at Stanford University, David is the co-founder of two venture-backed companies, including Neosensory, which is a pioneering wrist device that enables the deaf to hear. Yep, that's right. David is fascinating, and hopefully this conversation lives up to his capacity: We discuss the malleability of the brain to adjust to its inputs, the roots of synesthesia, how those who are born blind and deaf can now use touch to see and hear, and why we dream. Ultimately, we explore just how it happens that a brain trapped in a dark vault can create the vibrancy of our existence. David is a TED speaker, a Guggenheim Fellow, and serves on several boards, including the American Brain Foundation and the The Long Now Foundation. He is the Chief Scientific Advisor for the Mind Science Foundation, and the winner of Claude Shannon Luminary Award from Bell Labs and the McGovern Award for Excellence in Biomedical Communication. What's cooler? He has served as the scientific advisor to several television shows (including Westworld and Perception). Ironically—considering we both host podcasts and David is a neuroscientist—we had some technical difficulties during our conversation, but the hope is that this is not perceptible to you!  MORE FROM DAVID EAGLEMAN: Livewired: The Inside Story of the Ever-Changing Brain The Brain: The Story of You Sum: Forty Tales from the Afterlives David's Podcast: “Inner Cosmos” David's Website Follow David on Instagram David's Company: Neosensory To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Dr. Frank L. Douglas is an award-winning industry veteran with three decades of experience in healthcare, pharmaceuticals, and entrepreneurship. He served as Executive Vice President, Chief Scientific Officer and Member of the Board of Management of large Pharmaceutical companies such as Aventis AG, now Sanofi, SA. Dr. Douglas recently served as CEO of THEVAX Genetics USA Inc. and Member of the Board of TheVax Genetics Vaccine Co. He is also the co-founder of Douglas Ahmed Consulting (DAC). Some of his past experiences include being President and CEO of the Austen BioInnovation Institute in Akron, Executive Vice President, Chief Scientific Officer and Member of the Board of Management of Aventis AG, Chief Scientific Advisor of Bayer Healthcare, AG, Founder and First Executive Director of the MIT Center for Biomedical Innovation, Professor of the Practice in the Massachusetts Institute of Technology (MIT) Sloan School of Management, MIT Departments of Chemistry, Biomedical Engineering and the Harvard-MIT Division of Health Science and Technology.Dr. Douglas holds a Ph.D. in physical chemistry and an M.D. from Cornell University. He did his internship and residency in internal medicine at the Johns Hopkins Medical Institute and a fellowship in neuroendocrinology at the National Institutes of Health. In addition to his impressive career achievements, Dr. Douglas has led clinical trials and presented on healthcare disparities at ROCHE Pharma, UK. He conducted workshops and case study presentations at HBCUs namely at Lehigh University and MIT, the University of Akron, and Weill Cornell Medical School.Dr. Douglas is the founder and CEO of SAFE HAVEN DIALOGUES LLC, and has also authored two groundbreaking books, entitled “Defining Moments of a Free Man from a Black Stream” and “Until You Walk in My Shoes: A Reframing Methodology to Overcome Systemic Discrimination".AWARDS- Global Pharmaceutical Research and Development Director of the Year Award in 2001 and 2004- Lifetime Achievement Award from the National Organization for the Professional Advancement of Black Chemists and Chemical Engineers in 2002- Black History Maker Award in 2007- Geoffrey Beene Foundation and GQ Rockstar of Science, and the Odyssey Award from the Center of Medicine in the Public Interest in 2010- Caribbean Heritage Award for Entrepreneurship in 2011

Sir Patrick Vallance said he saw the scheme would lead to increased Covid transmission

Spoiler alert - Yes! and so much more! Dr. David Spiegel @reveri serves as the Willson Professor and Associate Chair of Psychiatry & Behavioral Sciences at Stanford University School of Medicine.  With a remarkable body of work, Dr. Spiegel's contributions encompass thirteen published books, 425 scientific journal articles, and 175 book chapters spanning hypnosis, psychosocial oncology, stress physiology, trauma, and psychotherapy for stress, anxiety, and depression. Dr Spiegel is also the co-founder and Chief Scientific Advisor of revolutionary self-hypnosis app, Reveri. We discuss:  The definition of hypnosis? What happens in the brain during hypnosis? Why is self-hypnosis so effective for reducing, controlling or totally eliminating your alcohol intake? How can hypnosis make it easier to control or eliminate alcohol consumption?  For more information on hypnotizability, please see here: https://www.reveri.com/hypnotizability-test Dr Spiegel has created Reveri, a self-hypnosis app based on his 45+ years of experience practising clinical hypnosis for a number of therapeutic purposes. Reveri offers clinically-backed hypnosis which you can utilise at home, for the fraction of the cost of an in-person hypnosis session. The app includes Dr Spiegel's unique hypnotisability test, which gives users an insight into how their brain functions in relation to hypnosis - their unique “Brain Style”. Reveri members have overcome many challenges using the app, such as quitting a 17 year long smoking habit, battling agoraphobia and using hypnosis instead of medication after surgery. Anyone, anywhere can access the immediate benefits of self-hypnosis through Reveri and work towards their goals––from breaking a bad habit to improving sleep, reducing pain or stress, establishing healthy eating habits and so much more.  Many Reveri members experience the benefits of self-hypnosis after a single 10-minute session. Hypnosis is the act of putting your brain in a state of intense focus and adaptability, making it the ideal environment for creating meaningful change in your life. Alcohol Free Life listeners can use this link to try Reveri, free for 14 days. Please tap the link from your mobile: https://reverihealth.app.link/janey Janey shares info about some upcoming events - Connection is the opposite of addiction! Join us this weekend for Champneys November 15 for a live zoom breathwork session with @raerituals November 16 Woodland venue in Bovingdon Herts Nov 22 zoom What does it mean to be a Sober Coach ? Register or get tickets for all events at https://www.thesoberclub.com/events/

In this week's episode, I am joined by Dr. Frank L. Douglas, PH.D., M.D. to discuss the negative impact of anxiety, stress, and discrimination in the workplace. His extensive education and experience allow him to speak with great insight and authority on this important topic. Dr. Douglas believes that personal problems can be reframed to produce better outcomes and increase personal satisfaction. Dr. Douglas is an award-winning industry veteran with three decades of experience in healthcare, the pharmaceutical industry, and entrepreneurship. Dr. Douglas holds a Ph.D. in physical chemistry and an M.D. from Cornell University. He completed his internship and residency in internal medicine at the Johns Hopkins Medical Institution and a fellowship in neuroendocrinology at the National Institutes of Health. In spite of episodes of discrimination, Dr. Douglas became the first Black member to be on the board of management of a top 5 global pharmaceutical company. This makes him an excellent choice for lecturing on these revelatory topics. Additionally, Dr. Douglas served as Executive Vice President, Chief Scientific Officer, and Member of the Board of Management of large pharmaceutical companies such as Aventis SA (now Sanofi, SA). Some of his past experiences include being President and CEO of the Austen BioInnovation Institute in Akron; Chief Scientific Advisor of Bayer Healthcare, AG; Founder and First Executive Director of the MIT Center for Biomedical Innovation; Professor of the Practice at the MIT Sloan School of Management and the Harvard-MIT Division of Health, Science, and Technology. Tune in to this week's episode to learn: The importance of diversity and inclusion in the workplace and how it relates to various aspects of organizational success The relationship between workplace stress and its connection to diversity and inclusion efforts, including employee well-being Potential consequences for organizations that fail to prioritize diversity and inclusion Strategies to enhance productivity through fostering a diverse and inclusive environment Practical approaches for tackling discrimination in the workplace and the role of leadership  Grab your drink of choice and join the conversation! Disclaimer The Healthcare Provider Happy Hour Podcast makes no warranty, guarantee, or representation as to the accuracy or sufficiency of the information featured in this Podcast. The information, opinions, and recommendations presented in this podcast are for general information only and any reliance on the information provided in this podcast is done at your own risk. This podcast should not be considered professional advice. Please speak with your own healthcare practitioner when seeking medical advice. Resources Connect with Dr. Douglas Website: https://safehavendialogues-llc.com/  Sponsorship Mindset Gap: Use referral code JENCAN20 when emailing assist@themindsetgap.com. The Mindset Gap is a boutique consultancy firm arming employees and leaders with mindset tools to increase productivity, bounce forward from adversity, and reset intention. Visit www.themindsetgap.com for more information today. Connect with Jennifer George: @bestobsessed_with_jenn | Instagram Jennifer George | Website @jenngeorge08) | Twitter Jennifer George | Facebook Click here to check out my book about connecting and communicating with patients to empower their experiences! Stay up to date on everything happening with the Healthcare Provider Happy Hour by subscribing to my weekly newsletter at www.jennifergeorge.co 

A new test being developed to check how toxic fish are from Lough Neagh

In this episode, we expose the Cargill family, and the grip they hold on the international agri-business, and why they care about what's going on in Ukraine. We also have 2 bonus audio clips. Dr Mike Yeadon, former Chief Scientific Advisor at PFIZER, is speaking out about the atrocities he is seeing since the C19 vaccine rollout. Our second clip is a classic audio clip from Dr. Rod Parsley from 2003, entitled "National Debt! To whom do we owe it?". Email us" thefacthunter@mail.comWebsite: thefacthunter.comShow notes: September 13th, 9 PM ET will be our listener call in show, live on our website thefacthunter.comCargill familyhttps://en.wikipedia.org/wiki/Cargill_familyMonsanto and BlackRock are buying up Ukrainehttps://freewestmedia.com/2022/08/06/monsanto-and-blackrock-are-buying-up-ukraine/Soaring food prices push more Cargill family members on to world's richest 500 listhttps://www.theguardian.com/news/2022/apr/17/soaring-food-prices-push-more-cargill-family-members-on-to-world-richest-500-listANNE RAY FOUNDATION 990https://projects.propublica.org/nonprofits/organizations/471036008/202103149349307900/fullMARGARET A CARGILL FOUNDATION 990https://projects.propublica.org/nonprofits/organizations/371758406/202223189349103032/fullWhat you didn't know about the C19 vaccine - Dr. Mike Yeadonhttps://www.brighteon.com/7fcef3ed-3771-4bdd-8061-fc2f5fea6ab4National Debt! To whom do we owe it? (2003 Rod Parsley)https://www.youtube.com/watch?v=rp3gTp1nGLYThe pit; The Epic of the Wheat. A Deal in Wheat, and Other Stories of the New and Old West by Frank Norrishttps://bookshop.org/p/books/the-pit-the-epic-of-the-wheat-a-deal-in-wheat-and-other-stories-of-the-new-and-old-west-frank-norris/19582212

Vetting companies and new technologies correctly can mean the difference between success and failure for VCs and the C-Suite. In this episode, Adam Torres and Dr. Martin Trevino, Cognitive Neuroscientist & Chief Scientific Advisor, explore what it takes to vet technologies and companies for investment.   Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule.Apply to be a guest on our podcast:https://missionmatters.lpages.co/podcastguest/Visit our website:https://missionmatters.com/Support the showMore FREE content from Mission Matters here: https://linktr.ee/missionmattersmedia

Vetting companies and new technologies correctly can mean the difference between success and failure for VCs and the C-Suite. In this episode, Adam Torres and Dr. Martin Trevino, Cognitive Neuroscientist & Chief Scientific Advisor, explore what it takes to vet technologies and companies for investment.   Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule.Apply to be a guest on our podcast:https://missionmatters.lpages.co/podcastguest/Visit our website:https://missionmatters.com/More FREE content from Mission Matters here: https://linktr.ee/missionmattersmedia

As helpful as traditional therapy can be, there simply aren't enough affordable therapists for everyone who needs mental health care. To address this growing problem, companies like Akili Interactive use technology to create innovative, accessible solutions for treating psychological disorders.  In this episode, Dr. Adam Gazzaley (co-founder and Chief Scientific Advisor) and Dr. Scott Kollins (Chief Medical Officer) tell us about how Akili made the groundbreaking video game that has FDA approval to treat Attention-Deficit/Hyperactivity Disorder (ADHD). We discuss how the game "EndeavorOTC" works and the potential for digital tools for mental health. Check out EndeavorOTC on Instagram and TikTokThe team at Akili has provided a special link offering a discounted annual subscription for EndeavorOTC! Instructions for redeeming the discount: 1) Download EndeavorOTC from the iOS app store. 2) Copy and paste the URL into your browser: https://apps.apple.com/redeem?ctx=offercodes&id=6447322997&code=HWM4TWJTYT6JLPRWJR&pt=1026987&mt=8&ct=HWM4TWJTYT6JLPRWJR3) Redeem the offer and get started! Please note: If you copy & paste the URL into your browser before downloading EndeavorOTC, be sure to download after you redeem the offer. It may not always happen on "auto-download" from the iOS app store. Learn more about Akili or EndeavorOTC or EndeavorRX*Note: Akili is not paying us, we just think they're cool. Support the showFor more info about this podcast, check out: www.alittlehelpforourfriends.comFollow us on Instagram: @ALittleHelpForOurFriends

There are almost a million people in the UK living with dementia, and Alzheimer's is the most common form. But the disease actually starts long before any noticeable symptoms appear, and over the past decade, studies have shown that it is much more complex than previously thought. Julie Williams has been at the forefront of this effort, uncovering the genes that make us susceptible, and has transformed our understanding of this devastating disease. She has brought researchers together to create bigger datasets and more powerful studies. Her current work with scientists from other fields, like immunology and computational biology, is looking at the mechanisms underlying Alzheimer's disease. Julie tells Jim about her early interest in science, her time as Chief Scientific Advisor to the Welsh government, and her belief in ‘team science' – collaborating and sharing research findings across international borders and disciplines. Produced by Florian Bohr

Tara Youngblood, sleep scientists and co-founder of ChiliSleep, joins show to tell you the best ways to get better sleep: Is 8 hours of sleep a myth? What is the best way to find out what works best for you? Can we “make up” on lost sleep? How to set up a “successful sleep.” Deep sleep is interrupted after this time of night. How to optimize your deep sleep switch. Blue light disrupts sleep. Cuddling and the hormones it helps for sleep. How to optimize sleep when traveling. The best body practice for sleep. What is the best temperature to sleep in? Can we take a hot shower before bed? Eating late and sleeping. Every disease is affected by lack of sleep. Knowledge Bomb: Dr. G determines if the latest Tik Tok trends are myth or fact. Rice water and hair growth. Internal shower for flat stomach. Oil pulling. Bone broth. Nature's cereal. Cycle syncing. Guest Bio: Tara Youngblood is sleep scientist, and Co-founder and Chief Scientific Advisor of sleepme - a company that creates award-winning technologies and apps that are changing the way the world sleeps. She is also CEO and co-inventor of Chili Sleep Products, whose revolutionary Chili Cool Mesh™ signature product has been used by Presidents, celebrities, and CEOs. Additionally, she is an international speaker, author, and has been a part of TEDx. Ads: Athletic Greens: To make it easy, AG1 is going to give you a FREE 1 year supply of immune-supporting Vitamin D AND 5 FREE travel packs with your first purchase. All you have to do is visit athleticgreens.com/healthyself. Athleticgreens.com/healthyself to take ownership over your health and pick up the ultimate daily nutritional insurance! BiOptimizers: Get 10% off on Magnesium Breakthrough with drg10 - and for a limited time only if you buy 3 bottles you can get exciting Gifts with Purchases like Blue light-blocking glasses and more!  This is a limited time offer for select orders. Don't wait, go now to magbreakthrough.com/drg MitoPure: Timeline is offering 10% off your first order of Mitopure. Go to timelinenutrition.com/DRG and use code DRG to get 10% off your order. Be sure to like and subscribe to #healthyself Hosted by Doctor Christian Gonzalez N.D. Follow Doctor G on Instagram @doctor.gonzalez

LifeBlood: We talked about how to live better and longer, what NAD is and how it impacts metabolism, how to become more physically resilient, and how to restore damaged cells, with Dr. Charles Brenner, Chief Scientific Advisor at ChromaDex, researcher and healthy aging advocate.    Listen to learn why aging is a privilege! You can learn more about Charles at BrennerLab.net, TruNiagen.com, Chromadex.com, Twitter and LinkedIn. Use discount code TAKE20 for $20 off purchases $150 or more. “These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.” Thanks, as always for listening! If you got some value and enjoyed the show, please leave us a review here: ​​https://ratethispodcast.com/lifebloodpodcast You can learn more about us at LifeBlood.Live, Twitter, LinkedIn, Instagram, YouTube and Facebook or you'd like to be a guest on the show, contact us at contact@LifeBlood.Live.  Stay up to date by getting our monthly updates. Want to say “Thanks!” You can buy us a cup of coffee. https://www.buymeacoffee.com/lifeblood

In a special live event held in partnership with The Conduit, we welcomed Sir David King, the former Chief Scientific Advisor to the UK Government and the Chairman of the Centre for Climate Repair at the University of Cambridge; Sian Sutherland, the co-founder of A Plastic Planet, a global campaign aimed at reducing plastic pollution; and Ari Helgason, a climate technology investor who is passionate about finding and funding innovative solutions to the climate crisis. Their moderator was Pictet's Christoph Courth Head of Philanthropy Services at Pictet Wealth Management. They discuss how climate change impacts ecosystems and the species that rely on them and explore some of the innovative and ground-breaking solutions that are being developed to mitigate the effects of climate change and restore damaged ecosystems.

On this podcast, we're going to talk about Brain Chemistry, specifically, what happens in our brains when we are traumatized, severely depressed, or anxious. And for those stuck in that state, what are the latest clinical treatments using medication, that can help someone get unstuck. My guest on this episode is the distinguished  Dr. John Krystal MD. Dr. Krystal is the Professor of Psychiatry, Neuroscience, and Psychology; Chair of the Department of Psychiatry at Yale University; and Chief of Psychiatry and Behavioral Health at Yale-New Haven Hospital. Dr. Krystal is a leading expert in the areas of alcoholism, post-traumatic stress disorder, schizophrenia, and depression. His work links psychopharmacology, neuroimaging, molecular genetics, and computational neuroscience to study the neurobiology and treatment of these disorders. He is best known for leading the discovery of the rapid antidepressant effects of ketamine in depressed patients. He is the co-founder and Chief Scientific Advisor of Freedom Biosciences, a clinical-stage biotechnology platform developing next-generation ketamine and psychedelic therapeutics that recently emerged from stealth in August 2022.  On this show, we cover topics that include ... The neurobiology of a depressed brain The relationship between thought and brain chemistry Anxiety and its connection to depression Pharmacology; getting into the various medications for treating depression. How antidepressants were discovered The efficacy of current antidepressants The neuroscience of psychedelics in the treatment of severe depression and PTSD Ketamine therapy; benefits, risks, and treatment protocols (the different delivery mechanisms, dosages, etc.)  Since we do talk about substances like ketamine which has psychedelic-like properties, here is a disclaimer: I'm NOT a doctor, nor do I play one on the interwebs. None of the content in this podcast constitutes medical advice or should be construed as a recommendation to use any medications mentioned. There are psychological, physical, and sometimes legal risks with usage. Please consult your doctor before considering anything we discuss in this episode. All right, that all said, here is more information for you to consider.  Enjoy!  Much more For show notes and more, visit www.larryweeks.com 

Michael Kelly was Prince Philip Professor of Technology at the University of Cambridge during 2002-16 and Emeritus since 2016. His previous career in academia and industry concerned the physics of high-performance semiconductor devices and the manufacturability of nanoscale artefacts. His interest in climate science and mitigation was piqued by the UK Climate Change Act of 2008, where, as part-time Chief Scientific Advisor to the Department for Communities and Local Government for Her Majesty's Government, he assumed a leading role in defining the need for a national retrofit programme for the UK's building stock to help achieve a reduction in the 45% of the UK's CO2 emissions that came from heating air and water in buildings. During 2010-2016 he led the teaching of undergraduate and postgraduate engineers with a course ‘Present and Future Energy Systems, the study of how the UK get's its energy now and how it might in 2050. It was here that he first appreciated the scale of the retrofit programme, and in later extensions, the cost in terms of finance, materials and human resources, of achieving a Net-Zero Economy for the UK by 2050. https://www.csap.cam.ac.uk/network/michael-kelly/ —— Tom Nelson's Twitter: https://twitter.com/tan123 Substack: https://tomn.substack.com/ About Tom: https://tomnelson.blogspot.com/2022/03/about-me-tom-nelson.html Notes for climate skeptics: https://tomnelson.blogspot.com/2019/06/useful-notes-for-climate-skeptics.html ClimateGate emails: https://tomnelson.blogspot.com/p/climategate_05.html

This episode of the podcast may be one of my all-time favorites. Dr. Vojdani is one of the leaders in the science and study of the immune system and autoimmunity. If you have hypothyroidism, Hashimoto's thyroiditis, another autoimmune condition, or food intolerances you are going to want to listen to this podcast. (Maybe multiple times.) In this episode we discuss: The basics of the immune system Th1 vs TH2 The role of the immune system in thyroiditis and why thyroid antibodies may not be the bad boys we thought they were. What causes immune activation and autoimmunity Loss of tolerance Food intolerance testing And so much more... This episode is packed with awesome information from one of the leaders in the industry. Aristo Vojdani obtained his MSc and PhD in microbiology and clinical immunology from Bar-Ilan University, Israel, with postdoctoral studies in comparative immunology at UCLA and tumor immunology at Charles Drew/UCLA School of Medicine and Science. He is a Clinical Professor at Loma Linda University in California, and an Adjunct Professor at the Lincoln College of Professional, Graduate and Continuing Education at the National University of Health Sciences.   Dr. Vojdani's ongoing research focuses on the role of environmental triggers in complex diseases, and he has developed more than 300 antibody assays for the detection of autoimmune disorders and other diseases. He has 17 US patents, over 200 articles, and two books, “Neuroimmunity and the Brain- Gut Connection” and “Food-Associated Autoimmunities: When Food Breaks Your Immune System,” to his name. He is the CEO of Immunosciences Lab in Los Angeles, California; the Chief Scientific Advisor for Cyrex Labs in Phoenix, Arizona; and, sits on the editorial board of five scientific journals. His many awards include the Herbert J. Rinkel Award (American Academy of Environmental Medicine), the Linus Pauling, PhD Award (American College for Advancement in Medicine), and the Personalized Lifestyle Medicine Institute Lifetime Achievement Award. Presently, Dr Vojdani is an Adjunct Associate Professor in the Department of Preventive Medicine at Loma Linda University in California, and an Adjunct Professor at the Lincoln College of Professional, graduate and continuing education at the National University of Health Sciences. He lectures at scientific and medical conferences around the world, spreading his knowledge and thereby improving the lives of patients once thought lost.

Dr. John Krystal — All Things Ketamine, The Most Comprehensive Podcast Episode Ever | Brought to you by Athletic Greens all-in-one nutritional supplement, Helix Sleep premium mattresses, and Allform premium, modular furniture. Dr. John Krystal is the Robert L. McNeil, Jr., Professor of Translational Research; Professor of Psychiatry, Neuroscience, and Psychology; Chair of the Department of Psychiatry at Yale University; and Chief of Psychiatry and Behavioral Health at Yale-New Haven Hospital.Dr. Krystal is a leading expert in the areas of alcoholism, post-traumatic stress disorder, schizophrenia, and depression. His work links psychopharmacology, neuroimaging, molecular genetics, and computational neuroscience to study the neurobiology and treatment of these disorders. He is best known for leading the discovery of the rapid antidepressant effects of ketamine in depressed patients.He directs/co-directs the Yale Center for Clinical Investigation (CTSA), NIAAA Center for the Translational Neuroscience of Alcoholism, and Clinical Neuroscience Division of the National Center for PTSD (VA).Dr. Krystal is a member of the U.S. National Academy of Medicine; co-director of the Neuroscience Forum of the U.S. National Academies of Sciences, Engineering, and Medicine; Fellow of the American Association for the Advancement of Science (AAAS); and editor of Biological Psychiatry, one of the most selective and highly cited journals in the field of psychiatric neuroscience.He is the co-founder and Chief Scientific Advisor of Freedom Biosciences, a clinical-stage biotechnology platform developing next-generation ketamine and psychedelic therapeutics that recently emerged from stealth in August 2022.ONE VERY IMPORTANT DISCLAIMER: I'm not a doctor, nor do I play one on the Internet. None of the content in this podcast constitutes medical advice or should be construed as a recommendation to use ketamine or psychedelics. There are psychological, physical, and sometimes legal risks with such usage. Please consult your doctor before considering anything we discuss in this episode.Please enjoy!*This episode is brought to you by Helix Sleep! Helix was selected as the #1 overall mattress of 2020 by GQ magazine, Wired, Apartment Therapy, and many others. With Helix, there's a specific mattress to meet each and every body's unique comfort needs. Just take their quiz—only two minutes to complete—that matches your body type and sleep preferences to the perfect mattress for you. They have a 10-year warranty, and you get to try it out for a hundred nights, risk-free. They'll even pick it up from you if you don't love it. And now, Helix is offering up to 200 dollars off all mattress orders plus two free pillows at HelixSleep.com/Tim.*This episode is also brought to you by Athletic Greens. I get asked all the time, “If you could use only one supplement, what would it be?” My answer is usually AG1 by Athletic Greens, my all-in-one nutritional insurance. I recommended it in The 4-Hour Body in 2010 and did not get paid to do so. I do my best with nutrient-dense meals, of course, but AG further covers my bases with vitamins, minerals, and whole-food-sourced micronutrients that support gut health and the immune system. Right now, Athletic Greens is offering you their Vitamin D Liquid Formula free with your first subscription purchase—a vital nutrient for a strong immune system and strong bones. Visit AthleticGreens.com/Tim to claim this special offer today and receive the free Vitamin D Liquid Formula (and five free travel packs) with your first subscription purchase! That's up to a one-year supply of Vitamin D as added value when you try their delicious and comprehensive all-in-one daily greens product.*This episode is also brought to you by Allform! If you've been listening to the podcast for a while, you've probably heard me talk about Helix Sleep mattresses, which I've been using since 2017. They also launched a company called Allform that makes premium, customizable sofas and chairs shipped right to your door—at a fraction of the cost of traditional stores. You can pick your fabric (and they're all spill, stain, and scratch resistant), the sofa color, the color of the legs, and the sofa size and shape to make sure it's perfect for you and your home.Allform arrives in just 3–7 days, and you can assemble it yourself in a few minutes—no tools needed. To find your perfect sofa and receive 20% off all orders, check out Allform.com/Tim.*For show notes and past guests on The Tim Ferriss Show, please visit tim.blog/podcast.For deals from sponsors of The Tim Ferriss Show, please visit tim.blog/podcast-sponsorsSign up for Tim's email newsletter (5-Bullet Friday) at tim.blog/friday.For transcripts of episodes, go to tim.blog/transcripts.Discover Tim's books: tim.blog/books.Follow Tim:Twitter: twitter.com/tferriss Instagram: instagram.com/timferrissYouTube: youtube.com/timferrissFacebook: facebook.com/timferriss LinkedIn: linkedin.com/in/timferrissPast guests on The Tim Ferriss Show include Jerry Seinfeld, Hugh Jackman, Dr. Jane Goodall, LeBron James, Kevin Hart, Doris Kearns Goodwin, Jamie Foxx, Matthew McConaughey, Esther Perel, Elizabeth Gilbert, Terry Crews, Sia, Yuval Noah Harari, Malcolm Gladwell, Madeleine Albright, Cheryl Strayed, Jim Collins, Mary Karr, Maria Popova, Sam Harris, Michael Phelps, Bob Iger, Edward Norton, Arnold Schwarzenegger, Neil Strauss, Ken Burns, Maria Sharapova, Marc Andreessen, Neil Gaiman, Neil de Grasse Tyson, Jocko Willink, Daniel Ek, Kelly Slater, Dr. Peter Attia, Seth Godin, Howard Marks, Dr. Brené Brown, Eric Schmidt, Michael Lewis, Joe Gebbia, Michael Pollan, Dr. Jordan Peterson, Vince Vaughn, Brian Koppelman, Ramit Sethi, Dax Shepard, Tony Robbins, Jim Dethmer, Dan Harris, Ray Dalio, Naval Ravikant, Vitalik Buterin, Elizabeth Lesser, Amanda Palmer, Katie Haun, Sir Richard Branson, Chuck Palahniuk, Arianna Huffington, Reid Hoffman, Bill Burr, Whitney Cummings, Rick Rubin, Dr. Vivek Murthy, Darren Aronofsky, Margaret Atwood, Mark Zuckerberg, Peter Thiel, Dr. Gabor Maté, Anne Lamott, Sarah Silverman, Dr. Andrew Huberman, and many more.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Mark Willis discusses his upcoming Distinguished Instructor Short Course, "Distributed acoustic sensing for seismic measurements – what geophysicists and engineers need to know." Geoscientists and engineers are very comfortable using seismic data sets acquired with geophones, hydrophones, and accelerometers because they have a long, well-defined set of standards for acquiring, processing, and interpreting them. However, distributed acoustic sensing (DAS) seismic measurements are rapidly augmenting and, in some cases replacing the data from these conventional tools. In this conversation with host Andrew Geary, Mark helps geoscientists and engineers build intuition and understanding of DAS seismic technology's value, limitations, and applications. Mark also discusses the most common objection to DAS, when DAS is better than conventional seismic acquisition, and tips for someone planning their first DAS seismic survey. Mark will be teaching this course for the first time at IMAGE, and this is a great preview of the valuable, insightful, and helpful tools and resources you will gain from this course. RELATED LINKS * Register for Mark's course at IMAGE - 26 August (https://seg.org/shop/products/detail/443222174) * Learn more about Mark's course and see the latest schedule (https://seg.org/Education/Courses/DISC/2022-2023-DISC-Mark-Willis) * SEAFOM (https://seafom.com/) * Discover SEG on Demand (https://seg.org/Education/SEG-on-Demand) * See the entire archive of the SEG podcast (https://seg.org/podcast) BIOGRAPHY Mark E. Willis is the Chief Scientific Advisor of Borehole Seismics at Halliburton. He is responsible for mentoring technologists, developing and promoting geophysical innovations, and fostering long-term client relationships. Previous to joining Halliburton in 2011, he worked in various research technology, supervisory, and management positions at Mobil Oil, Cambridge GeoSciences, Massachusetts Institute of Technology Earth Resources Laboratory, and ConocoPhillips. In his career, he has performed research and development in distributed acoustic sensing, VSP technology, deep sonic log imaging, fracture identification using seismic data (time-lapse VSP, microseismics, and surface seismic scattering), interferometric imaging, Kirchhoff and reverse time depth migration, full waveform inversion, machine learning, velocity model building, and sonic waveform processing. Willis holds a B.S. in Applied Math and Physics from the University of Wisconsin – Milwaukee and a Ph.D. in Geophysics from MIT. He has written over 100 papers, publications, and presentations and holds multiple patents. He is a member of the SEG, EAGE, SSA, SPWLA, and ASA. CREDITS SEG produces Seismic Soundoff to benefit its members, the scientific community, and inform the public on the value of geophysics. Please leave a 5-star rating on Apple Podcasts and Spotify to show your support for the show. It takes less than five seconds to leave a 5-star rating and is the number one action you can take to show your appreciation for this free resource. And follow the podcast while you are on the app to be notified when each new episode releases. Original music created by Zach Bridges. Andrew Geary hosted, edited, and produced this episode for 51 features, LLC. Thank you to the SEG podcast team: Jennifer Cobb, Kathy Gamble, and Ally McGinnis.

Epaminondas is the UNESCO Chair on Futures Research Hellas and the Chief Scientific Advisor to the Special Secretariat for Foresight at the Presidency of the Greek government

We know meat is problematic for the environment, and seafood has its own issues with overfishing, so do we have to wave goodbye to the foods we love? Well, what if we told you that there are substitutes which you can enjoy without sacrificing taste and texture? We start with mycoprotein, in the form of the well-known meat substitute products of Quorn Foods. Tim Finnigan, Chief Scientific Advisor for Quorn Foods, explains why mycoprotein is such a suitable source of protein, how it is manufactured, the environmental benefits, and how fusarium venenatum, the microfungus, was discovered. And... it's tasty! In the same episode, we ask Dr Lauran Madden, Chief Technology Officer at BlueNalu, to share with you the engineering process, the health and environmental benefits, and the positive impact on the environment of their cell-cultured seafood. This is hugely critical as the populations of marine species have halved since 1970, battling with overfishing, illegal fishing, and the effects of trawling. This cell-cultured seafood comes first...plaice... *sorry*. By the end of this episode, we will hopefully have demonstrated the environmental and health benefits of switching meat out of our diets for better alternatives. Keywords: cell-culture, microfungus, filamentous, mycoprotein, environment, meat substitute, protein, seafood, yeast, engineering, technologies, fish, fungi, Quorn, BlueNalu.

On this week's episode, we're joined by Dr. Moriba Jah to discuss space environmentalism and provide the latest update on our shared orbital domain.Moriba joined us here on Celestial Citizen Podcast in Season 1 and he is back again to discuss the recent Russian anti-satellite test as an update to our space sustainability conversation from this past spring, as well as, share more about his new role as the Chief Scientific Advisor at the new space startup, Privateer.My guest on today's show, Dr. Moriba Jah, joined the Oden Institute core faculty in 2018 at the University of Texas at Austin, and is currently serving as an Associate Professor at the Department of Aerospace Engineering and Engineering Mechanics.  As previously stated, Moriba is also the Chief Scientific Advisor at Privateer, a much-anticipated space startup that aims to tackle humanity's ever-increasing space debris problem.  He is also the Program Lead of Space Security, Safety, and Sustainability at the Robert Strauss Center for International Security and Law, as well as, a research affiliate with the Space Enabled Group at MIT Media Lab.You can check out the first episode of Shifted Space (mentioned in this episode) which is part of a documentary series featuring Dr. Moriba Jah and focusing on the interconnectedness between land, sea, and sky.Support the show (https://donorbox.org/celestial-citizen)